Purple Biotech (PPBT) 20-F 9 Mar 22 2021 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2021shares
Document Information Line Items
Entity Registrant Name	Purple Biotech Ltd.
Trading Symbol	PPBT
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	178,001,092
Amendment Flag	false
Entity Central Index Key	0001614744
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-37643
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	4 Oppenheimer Street
Entity Address, Address Line Two	Science Park
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670104
Entity Address, Country	IL
Title of 12(b) Security	American Depositary Shares, each representing 10 Ordinary Shares (1
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	Somekh Chaikin
Auditor Location	Tel Aviv, Israel
Auditor Firm ID	1057
Business Contact
Document Information Line Items
Entity Address, Address Line One	4 Oppenheimer Street
Entity Address, Address Line Two	Science Park
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670104
Entity Address, Country	IL
Contact Personnel Name	Gil Efron
Contact Personnel Fax Number	+972-3-5097196
City Area Code	+972
Local Phone Number	3-933-3121

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 10,890	$ 11,247
Short term deposits	36,310	46,558
Trade receivables		500
Other current assets	1,273	977
Total current assets	48,473	59,282
Non-current assets
Other investment	187
Right to use assets	619	790
Fixed assets, net	277	178
Long term deposits	160	3,071
Intangible assets	20,482	20,482
Total assets	70,198	83,803
Liabilities
Current maturity of lease liabilities	199	207
Accounts payable	1,473	1,198
Other payables	2,578	1,693
Total current liabilities	4,250	3,098
Non-current liabilities
Lease liability	550	688
Post-employment benefit liabilities	292	265
Total non - current liabilities	842	953
Equity
Share capital, no par value
Share premium	123,951	118,909
Receipts on account of warrants	28,017	29,984
Capital reserve for share-based payments	8,862	8,115
Capital reserve from transactions with related parties	761	761
Capital reserve from transactions with non- controlling interest	(859)	(859)
Accumulated loss	(95,905)	(77,521)
Equity attributable to owners of the Company	64,827	79,389
Non-controlling interests	279	363
Total equity	65,106	79,752
Total liabilities and equity	$ 70,198	$ 83,803

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	[1]	Dec. 31, 2019	[1]
Profit or loss [abstract]
Research and development expenses	$ 11,827	$ 7,238		$ 2,278
Sales, general and administrative expenses	6,107	6,001		4,393
Operating Loss	17,934	13,239		6,671
Expenses (income) on account of warrants		15,655		(1,509)
Finance expenses	212	61		181
Finance income	(320)	(254)		(151)
Finance expenses (income), net	(108)	15,462		(1,479)
Tax expenses, net				216
Loss for the year from continuing operations	17,826	28,701		5,408
Loss (profit) from discontinued operation	642	(627)		485
Loss attributable to:
Owners of the Company	18,384	27,999		5,850
Non-controlling interests	84	75		43
Total Loss attributable	$ 18,468	$ 28,074		$ 5,893
Continuing operations
Basic & diluted loss per ADS - USD (in Dollars per share)	$ 1.01	$ 2.5		$ 2.75
Number of ADSs used in calculating basic & diluted loss per ADS (in Shares)	17,568,036	11,500,113		1,936,778
Discontinued operation
Basic & diluted loss (profit) per ADS – USD (in Dollars per share)	$ 0.04	$ (0.05)		$ 0.25
Number of ADSs used in calculating basic & diluted loss (profit) per ADS (in Shares)	17,568,036	11,500,113		1,936,778
[1]	Restated , see Note 4 discontinued operation.

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share Capital	Share premium	Receipts on account of warrants	Capital reserve for share-based payments	Capital reserve from transactions with related parties	Capital reserve from transactions with Non-controlling interest	Accumulated loss	Equity attributable to owners of parent	Non-controlling interests	Total
Balance at Dec. 31, 2018		$ 44,597	$ 7,982	$ 1,714	$ 761	$ (859)	$ (43,672)	$ 10,523	$ 481	$ 11,004
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		2,200		298				2,498		2,498
Issuance of shares due to RSUs vesting		104		(104)
Exercise of warrants		85	(42)					43		43
Share-based payments				1,273				1,273		1,273
Transfer of derivative instrument from liability to equity (see Note 10D)			1,934					1,934		1,934
Total transactions with owners of the Company		2,389	1,892	1,467				5,748		5,748
Loss for the year							(5,850)	(5,850)	(43)	(5,893)
Balance at Dec. 31, 2019		46,986	9,874	3,181	761	(859)	(49,522)	10,421	438	10,859
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		21,200	14,825	2,723				38,748		38,748
Exercise of warrants		38,013	(23,780)	455				14,688		14,688
Share-based payments		889		1,756				2,645		2,645
Transfer of derivative instrument from liability to equity (see Note 10D)			27,386					27,386		27,386
ADS and warrants issued in connection with the purchase of a subsidiary (see Note 5B)		11,821	1,679					13,500		13,500
Total transactions with owners of the Company		71,923	20,110	4,934				96,967		96,967
Loss for the year							(27,999)	(27,999)	(75)	(28,074)
Balance at Dec. 31, 2020		118,909	29,984	8,115	761	(859)	(77,521)	79,389	363	79,752
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		540						540		540
Exercise of warrants		3,167	(1,967)					1,200		1,200
Share-based payments		1,335		747				2,082		2,082
Total transactions with owners of the Company		5,042	(1,967)	747				3,822		3,822
Loss for the year							(18,384)	(18,384)	(84)	(18,468)
Balance at Dec. 31, 2021		$ 123,951	$ 28,017	$ 8,862	$ 761	$ (859)	$ (95,905)	$ 64,827	$ 279	$ 65,106

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities from continuing operation:
Loss for the year from continuing operation	$ (17,826)	$ (28,701)	$ (5,408)
Adjustments:
Depreciation	231	235	178
Finance expenses (income), net	(108)	15,462	(1,479)
Share-based payments	2,082	2,645	1,273
Total adjustments	(15,621)	(10,359)	(5,436)
Changes in assets and liabilities:
Changes in trade receivables and other current assets	(316)	(492)	1,555
Changes in accounts payable	399	(2,355)	493
Changes in other payables	634	(571)	(77)
Changes in post-employment benefit liabilities	27	(20)	(148)
Changes in assets and liabilities, total	744	(3,438)	1,823
Net cash used in operating activities from continuing operation	(14,877)	(13,797)	(3,613)
Cash flows from investing activities from continuing operation:
Cash assumed as part of acquisition of FameWave (See Note 5B)		69
Investment in financial assets and loan granted (See Note 5B)			(2,100)
Decrease (increase) in short and long term deposits	13,162	(49,618)	1,511
Interest received	359	110	151
Acquisition of fixed assets	(115)	(156)	(11)
Net cash provided by (used in) investing activities from continuing operation	13,406	(49,595)	(449)
Cash flows from financing activities from continuing operation:
Proceeds from issuance of ADSs	564	27,925	2,594
ADS issuance expenses paid	(24)	(2,074)	(264)
Proceeds from issuance of warrants		26,574	3,406
Warrants issuance expenses paid		(3,281)	(347)
Proceeds from exercise of warrant	1,200	19,547	43
Repayment of lease liability	(153)	(179)	(171)
Interest paid	(75)	(24)	(28)
Net cash provided by financing activities from continuing operation	1,512	68,488	5,233
Cash flows in respect of discontinued operation as follows:
Net cash (used in) provided by operating activities	(374)	1,705	(1,968)
Net cash from investing activities
Net cash from financing activities
Net cash provided by (used in) discontinued operation	(374)	1,705	(1,968)
Net increase (decrease) in cash and cash equivalents	(333)	6,801	(797)
Cash and cash equivalents at the beginning of the year	11,247	4,385	5,163
Effect of translation adjustments on cash and cash equivalents	(24)	61	19
Cash and cash equivalents at end of the year	10,890	11,247	4,385
Non- Cash activities:
Reclassification of non-tradable derivatives until registered for trading		$ 27,386	$ 1,934

General

General	12 Months Ended
	Dec. 31, 2021
Disclosure General [Abstract]
General	Note 1 - General Reporting entity A. Purple Biotech Ltd. (hereinafter: the “Company “Purple” The Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company’s shares. In December 2020 the Company changed its name from Kitov Pharma Ltd to Purple Biotech Ltd. B. The Company’s securities (American Depository Shares (“ADS”)) were listed for trading on the NASDAQ in November 2015 (including a Serries A warrant that expired in November 2020). Each ADS represents 10 ordinary shares with no par value following a reverse split in effect from August 23, 2020 (see Note 10A). Each 10 warrants enable the purchase of 1 ADS. The Company’s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel. C. In January 2017, the Company acquired the majority of shares of TyrNovo Ltd. (hereinafter: “ TyrNovo In January 2020, the Company acquired 100% of FameWave Ltd. (hereinafter “FameWave”), see also Note 5B. In October 28, 2021, the Company established a fully owned subsidiary Purple Biotech GmbH (hereinafter “Purple GmbH”). The Company together with TyrNovo, FameWave and Purple GmbH are referred to, in these consolidated financial statements, as “ the Group D. Since incorporation through December 31, 2021, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated deficit of USD 95.9 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2021, the Company raised a total of USD 94.4 million net (excluding exercise of warrants), see also Note 10. E. While the COVID-19 pandemic has affected our operations to date to a certain extent such as product sales and operation of clinical studies, the extent to which the COVID-19 pandemic may impact our operations in the future will depend on future developments. In particular, the continued spread of COVID-19 globally could materially adversely impact our operations and workforce, including our manufacturing activities and clinical trials, as well as our ability to continue to raise capital. F. The Company decided to discontinue Consensi operation. Consequently, the Company is reporting Consensi as a discontinued operation and on December 31, 2021 has one operating segment- oncology, see also Note 4.

Basis of Preparation of the Con

Basis of Preparation of the Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2021
Disclosure of basis of preparation of financial statements [text block] [Abstract]
Basis of Preparation of the Consolidated Financial Statements	Note 2 - Basis of Preparation of the Consolidated Financial Statements A. Statement of compliance with International Financial Reporting Standards The Group has prepared the consolidated financial statements in accordance with International Financial Reporting Standards (hereinafter: “IFRS”), as issued by the International Accounting Standard Board (“IASB”). These consolidated financial statements were approved by the board of directors on March 7, 2022. B. Functional and presentation currency These consolidated financial statements are presented in US dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates. C. Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except for the following assets and liabilities: ● Financial instruments and derivatives measured at fair value through profit or loss; ● Provisions; ● Liabilities for employee benefits For further information regarding the measurement of these assets and liabilities see Note 3 regarding significant accounting policies. D. Use of estimates and judgment The preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group’s consolidated financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes: Estimate Principal assumptions Possible effects Reference Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities Recoverability of intangible assets The discounted cash flows method includes assumptions such as future expenses, future revenues, successes rate (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate. Impairment of the in-process research and development in profit or loss See Note 5 regarding subsidiaries Fair value measurement The Group’s management regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Group Audit Committee. When measuring the fair value of an asset or liability, the Group uses market observable data as much as possible. There are three levels of fair value measurements in the fair value hierarchy that are based on the data used in the measurement, as follows: - Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. - Level 2: inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. - Level 3: inputs that are not based on observable market data (unobservable inputs). Further information about the assumptions made in measuring fair value of share-based payments, intangible assets, financial asset, and financial instruments are included in Note 11, Note 5 and Note 19, respectively. E. Exchange rates and linkage bases Balances in foreign currency (mainly the New Israeli Shekel, or NIS) or linked thereto are included in the consolidated financial statements at the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position date. Data on exchange rates are as follows: Representative exchange rate of USD (NIS/USD 1) Date of consolidated financial statements: December 31, 2021 3.110 December 31, 2020 3.215 December 31, 2019 3.456 % Changes in exchange rates for the year ended: December 31, 2021 (3 ) December 31, 2020 (7 ) December 31, 2019 (7.8 )

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Disclosure of significant accounting policies [text block] [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements: A. Basis of consolidation 1. Acquisition of Subsidiaries The Group has acquired two subsidiaries in the past, see Note 5. Upon such acquisition, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts for the acquisition as a purchase of assets. To date, the two acquisitions made by the Company were determined to be an acquisition of assets, see Note 5. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. B. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end of the year. The foreign currency gain or loss on amortized items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. C. Financial instruments 1. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. Subsequent measurement and gains and losses Financial assets at fair value through profit or loss These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include: finance lease liabilities, accounts payables and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. 3. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3. 4. Share capital Ordinary shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects. Incremental costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. 5. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufactuing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo and Famewave (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment may be needed. E. Impairment Timing of impairment testing The carrying amounts of the Group’s non-financial assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use. Measurement of recoverable amount The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. Recognition of impairment loss An impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. F. Loss per share The Group presents basic and diluted loss per share data for its ordinary share capital. Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of 10 shares per 1 ADS. Diluted loss per share is determined by adjusting the profit or loss attributable to ordinary shareholders of the Company and the weighted average number of ordinary shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential ordinary shares, which comprise convertible debentures, share options and share options granted to employees. G. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. Defined contribution plans A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Short-term benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. I. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. J. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. A provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation can be estimated reliably. K. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria are met and collectability is probable Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract’s inception date, the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group considers the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The transaction price includes fixed amounts and amounts that may change as a result of discounts, refunds, credits, price concessions, incentives, performance bonuses, penalties, claims and disputes and contract modifications that the consideration in their respect has not yet been agreed by the parties. The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group’s promise to grant a license provides a customer with either a right to access the Group’s IP or a right-to-use the Group’s IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a “right-to-use” license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license. The license granted by the Company, which relates to its product is granted to a third party which can obtain direct use of, and substantially all of the remaining benefits from the license at the point in time at which the license is granted. The Group will not continue to be involved in any activities that significantly affect the IP at the specific territory. Therefore the Company recognized the license granted as right-to-use license. Principal or agent When another party is involved in providing goods or services to the customer, the Group examines whether the nature of its promise is a performance obligation to provide the defined goods or services itself, which means the Group is a principal and therefore recognizes revenue in the gross amount of the consideration, or to arrange that another party provide the goods or services which means the Group is an agent and therefore recognizes revenue in the amount of the net commission. The Group is engaged with a third party to manufacture its products for the Group’s customer (“the Manufacturing Agreement”). The Group is a principal when it controls the promised goods or services before their transfer to the customer. Indicators that the Group controls the goods or services before their transfer to the customer include, inter alia, as follows: the Group is the primary obligor for fulfilling the promises in the contract; the Group has inventory risk before the goods or services are transferred to the customer; and the Group has discretion in setting the prices of the goods or services. Accordingly, the Company accounts for the manufacturing agreement as an agent on a net basis. L. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of financial assets at fair value through profit or loss and income from short term deposits. Finance expenses include loss from exchange rate differences and interest fee. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities. M. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income to the extent they relate to items recognized directly in equity or in other comprehensive income. Current taxes Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Current taxes also include taxes in respect of prior years and any tax arising from dividends. Deferred taxes Deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized. The Company has yet to recognize deferred tax assets. N. Leases Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset’s use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected to account for the contract as a single lease component without separating the components. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-to-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-to-use asset After lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever earlier, as follows: office lease 5 years. O. Discontinued operations A discontinued operation is a component of the Group’s business that represents a separate major line of business that has been disposed of or is held for sale or distribution. Classification as a discontinued operation occurs upon disposal or when the operation meets the criteria to be classified as held for sale, if earlier. When an operation is classified as a discontinued operation, the comparative statement of operation is restated as if the operation had been discontinued from the start of the earliest comparative period.

Discontinued Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2021
Disclosure of discontinued operations [text block] [Abstract]
Discontinued operation	Note 4 - Discontinued operation In October 2021, the Company agreed, together with its then U.S distributor for Consensi, Coeptis Pharmaceuticals Inc., to terminate the distribution agreement. Despite the Company’s efforts to identify an alternative distributor for Consensi in the United States., the Company concluded that commercialization of Consensi, both in the U.S market and elsewhere, is not likely to generate significant revenue and achieve profitability in the near term. In order to reduce the expenses involved in maintaining the product, it was concluded to discontinue Consensi activities and to allocate the funds to the company’s core oncology activities. In parallel, the agreements with Kuhnil Pharmaceuticals Inc.’s for the territory of South Korea and Hebei Changshan Biochemical Pharmaceutical Co., Ltd. for the territory of China were terminated. Consensi represented a separate major line of business. Discontinuation also included inventory write off. Consequently, the Company is reporting Consensi as a discontinued operation and as of December 31, 2021 has one operating segment- oncology. 2021 2020 2019 USD thousands Results of discontinued operation Revenue - 1,000 1,000 Expenses 642 373 1,485 Loss (profit) for the year 642 (627 ) 485 Loss (profit) for the year attributable to the owners of the Company: From continuing operations 17,826 28,701 5,408 From discontinued operation 642 (627 ) 485 Loss (profit) per share – Discontinued operation Basic & diluted loss (profit) per ADS – USD 0.04 (0.05 ) 0.25 Cash flows from discontinued operation Net cash (used in) provide by operating activities (374 ) 1,705 (1,968 ) (374 ) 1,705 (1,968 )

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about intangible assets [text block] [Abstract]
Schedule of intangible assets	Note 5 - Intangible Assets As of December 31, 2021, and 2020: USD thousands IPR&D related to TyrNovo (see 5A below) 6,172 IPR&D related to Famewave (see 5B below) 14,310 Total intangible assets 20,482 A Acquisition of Tyrnovo 1. Pursuant to the terms of the transaction, the Company issued to GHP 564,625 of its Ordinary Shares (the “Consideration Shares”) and paid GHP aggregate cash proceeds of approximately USD 2 million (the “Cash Consideration”) in exchange for 9,570 Ordinary Shares in TyrNovo, which represented approximately 65% of TyrNovo’s shares. In addition, the Company was assigned a loan in the amount of USD 101 thousand which had been made by GHP to TyrNovo (the “TyrNovo Acquisition”). USD 167 thousand of the Cash Consideration was held back by the Company pending the fulfillment of certain conditions as agreed to between the Company and GHP. During 2019 the Company and GHP signed an agreement, according to which the Company paid GHP USD 91 thousand and the remaining amount of USD 76 thousand was retained by the Company to cover any future claims it might have with regards of any matter the above amount was withheld for and is waived by GHP. The Company wrote off this remaining liability in June 2019. Acquisition of the Company was accounted for as the acquisition of a group of assets and liabilities in view of the acquired company not being a business and therefore not meeting the definition of a business combination in IFRS 3. Accordingly, the transaction consideration was allocated proportionately to the identifiable assets and liabilities acquired, based on their fair value at the acquisition date. In addition, no goodwill was recognized and no deferred taxes were recognized in respect of the temporary difference that existed on the acquisition date. 2. Additional acquisition of minority shareholders In October 2017, the Company signed an agreement for the acquisition of an additional 27% stake in TyrNovo (the “Newly Acquired TyrNovo Shares”), from a group of unaffiliated minority shareholders of TyrNovo, who collectively held 4,024 ordinary shares, or approximately 27%, of TyrNovo. The closing of this transaction took place on March 15, 2018, following which the Company held approximately 91.9% of TyrNovo’s issued and outstanding ordinary shares. 3. Settlement with a minority shareholder In June 2018, the Company signed an agreement with a minority shareholder in TyrNovo, Taoz, for the acquisition of its holding in TyrNovo, which was approximately 4.1% of TyrNovo’s share capital. The closing of this transaction took place on June 15, 2018, following which the Company held approximately 97.4% of TyrNovo’s issued and outstanding ordinary shares. 4. Non-controlling interests Non-controlling interests are presented based on their proportionate interest in the recognized amount of the assets and liabilities of TyrNovo, see Note 10F. 5 During 2019, TyrNovo issued 13,750 shares to Purple which increased the Company’s direct ownership of equity from 97.6% to 98.47%. B. Acquisition of Famewave On March 14, 2019, the Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24, (“FameWave”) from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long-term lock-up period, priced at USD 12.3 per ADS, plus 50% warrant coverage based on an exercise price of USD 19.8 per ADS with a 4-year term. In addition, the Company provided a loan to FameWave of up to approximately USD 2 million to finance its operation until the closing of the acquisition. The acquisition closed on January 7, 2020. In consideration of the transfer of the FameWave shares to the Company and completion of the other condition set forth in the acquisition agreement, the aggregate purchase price paid by the Company for 100% of shareholders, and other stake holders (a) 807,561 of the Company’s ADSs, (b) warrants to purchase 403,781 additional ADSs with a term of exercise of 4 years beginning on the date of issuance, and subject to other terms and conditions as set forth herein and in the ‘warrant agreements of the Company (c) 54,472 RSUs and 27,236 options to purchase 27,236 shares of the Company. The consideration was recorded based on the fair value of the assets purchased. Under the terms of the agreement, OrbiMed, Pontifax and Arkin Holdings, leading life-science focused investment funds, exchanged their shares in FameWave for Purple ADSs and warrants, and invested USD 3.5 million in Purple in exchange for additional 284,553 newly issued ADSs of Purple. The acquisition was accounted for as an asset purchase as it does not meet the definition of a business combination in accordance with IFRS 3. At the closing date, FameWave did not include a system of inputs and processes, and at this stage had no outputs. In addition, most of the fair value of the acquired assets is attributable to a single identifiable asset which is the in-process research and development asset. In addition, no goodwill was recognized on the acquisition date, See below. Identifiable assets acquired and liabilities assumed The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Cash 69 Intangible assets (1) 14,310 Other receivables 6 Trade payables (2,283 ) Other payables (2,102 ) Total net identifiable assets 10,000 (1) In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise. The fair value of the assets and liabilities recognized at the acquisition date was determined according to the estimated fair value of those items. The fair value was estimated as the amount for which those items could be acquired or sold between a willing buyer and a willing seller in an arm’s length transaction. C As of December 31, 2021, the recoverable amount of the in-process research and development assets (hereinafter – “intangible assets”) was based on their value in use and was determined by discounting the future cash flows to be generated from them by using the discounted cash flows method, on the annual year test. The recoverable amount of the intangible assets exceeds their carrying amount, thus no impairment loss was recognized. The discount rate used for calculating intangible assets recoverable amount is 15.6%, in addition to taking into consideration the risks associated in drug candidates at this stage of development.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2021
Disclosure of cash and cash equivalents [text block] [Abstract]
Cash and Cash Equivalents	Note 6 - Cash and Cash Equivalents As of December 31 2021 2020 USD thousands Balance in USD 9,174 10,758 Balance in other currencies 1,716 489 Total cash and cash equivalents 10,890 11,247

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Note 7 – Leases The Company applies IFRS 16, Leases A. Information regarding material lease agreements The Company entered into an agreement for the lease of offices in Rehovot as from September 15, 2020 for a period of 5 years. Accordingly, the Company recognized in the statement of financial position a right-to-use asset in the amount of USD 817 thousand concurrently with the recognition of a lease liability in the same amount. The agreement has an option to extend the lease, for additional 5 years. This additional period is not considered in the calculation of the liability as the Company currently does not predict it will use this option. The Company has an option to extend the lease agreements for an additional 5 years at the terms as those of the existing agreement with additional of 5% to the current terms and CPI linked. B. Right-to-use assets Carrying amounts of right-to-use assets and movement during the period: Office Lease USD thousands Balance as at January 1, 2021 790 Depreciation on right-to-use assets (171 ) Change during the year - Balance as at December 31, 2021 619 Balance as at January 1, 2020 206 Depreciation on right-to-use assets (233 ) Change during the year 817 Balance as at December 31, 2020 790 C. Lease liability Maturity analysis of the Company’s lease liabilities December 31, December 31, 2021 2020 USD thousands USD thousands Less than one year 219 210 One to three years 658 840 Total 877 1,050 Current maturities of lease liability 199 207 Long-term lease liability 550 688 D. Additional information on leases Amounts recognized in profit or loss 2021 2020 USD thousands USD thousands Interest expenses on lease liability 65 41

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2021
Current Assets [Abstract]
Other Current Assets	Note 8 - Other Current Assets As of December, 31 2021 2020 USD thousands Government authorities 268 197 Prepaid expenses and other receivables 1,005 780 Total other current assets 1,273 977

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other payables [text block] [Abstract]
Other Payables	Note 9 - Other Payables As of December 31 2021 2020 USD thousands Due to related parties - payroll related 527 541 Accrued expenses 1,527 880 Government authorities 66 43 Payroll related 440 229 Other payables 18 - 2,578 1,693

Equity

Equity	12 Months Ended
	Dec. 31, 2021
Disclosure of share capital, reserves and other equity interest [text block] [Abstract]
Equity	Note 10 - Equity A. The Company’s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class. On August 21, 2020 the ratio between ADSs and shares was changed from 1:1 to 1:10 (each 1 ADS equals 10 shares). In these consolidated financial statements, all numbers of ADSs reflect the reverse share split and the ADS ratio change retrospectively. B. The Company’s share capital As of December 31, 2021 As of December, 31, 2020 Number of shares in thousands Authorized Issued and paid-in Authorized Issued and paid-in Shares, no par value 1,000,000 178,001 1,000,000 172,106 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 - C. Changes in share capital during the year For the year ended December 31 2021 2020 2019 Number of ADSs in thousands Issued as at January 1 17,211 1,956 1,600 Issuance of ADSs (See D below) 126 8,573 343 Vesting of RSUs 163 7 10 Exercise of warrants 300 6,675 3 Issued as at December 31 17,800 17,211 1,956 D. Financing rounds 1. On June 9, 2021, the Company entered into sales agreement with Jefferies LLC, for the sale of ADSs. In accordance with the terms of the sales agreement, the company may offer and sell ADSs having an aggregate offering price of up to $50,000,000 from time to time through Jefferies, acting as the company’s agent. During November and December 2021, the Company sold, under the sales agreement 126,160 ADSs under an “at-the-market” equity offering program (“ATM program”) at an average price of $4.46 per ADS. The Company raised USD 0.56 million gross (approximately USD 0.54 million net of placement agent fees and other offering related expenses). On June 25, 2020, in a registered direct offering on the NASDAQ, the Company raised USD 35 million gross (approximately USD 30.7 million net of placement agent fees including non- cash fees and other offering related expenses). In this registered direct offering, the Company issued an aggregate of 3,888,889 ADSs at a purchase price of USD 9 per ADS that were recorded in equity in the amount of USD 19,201 thousand net of issuance expenses. The Company also agreed to issue to the investors registered warrants to purchase up to an aggregate of 1,944,444 ADSs (hereinafter the “June 2020 warrants”) that were recorded in receipts on account of warrants at a value of USD 11,472 thousand net of issuance expenses. The registered June 2020 warrants have a term of 5 years and are exercisable immediately and have an exercise price of USD 9 per ADS. During 2021, 300 thousand ADS’s were exercised. In addition, the Company issued to the placement agent (or its designees) registered compensation warrants to purchase up to 194,443 ADSs at a value of USD 1,199 thousand which is included in the net amount raised above, at an exercise price of USD 11.25 per ADS. The registered placement agent warrants are immediately exercisable and have a term of 5 years from the date of the effective date of the offering. On May 8, 2020, in a registered direct offering on the NASDAQ, the Company raised USD 10 million gross (approximately USD 8.4 million net of placement agent fees including non- cash fees and other offering related expenses). In this registered direct offering, the Company issued an aggregate of 2,500,000 ADSs at a purchase price of USD 4 per ADS that were recorded in equity in the amount of USD 709 thousand net of issuance expenses. The Company issued to the investors unregistered warrants to purchase up to an aggregate of 2,500,000 ADSs (hereinafter the “May 2020 warrants”). These May 2020 warrants have a term of 5.5 years, are exercisable immediately and have an exercise price of USD 4 per ADS. The warrants were considered a derivative instrument (due to a cashless exercise feature), and were recorded as a liability in the amount of USD 9,157 thousand. On July 17, 2020 the warrants were listed for trading, and, as a result the cashless feature expired. Therefore, the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial expenses. The warrants fair value on the listing date was USD 16,403 thousand. In addition, the Company issued to the placement agent (or its designees) compensation warrants to purchase up to 175,000 ADSs at a value of USD 559 thousand which is included in the net amount raised above, at an exercise price of USD 5 per ADS. The placement agent warrants are immediately exercisable and have a term of 5 years from the date of the effective date of the offering. On April 19, 2020, the Company entered into warrant exercise letters, with certain institutional investors holding the March 2020 warrants (as detailed below) to purchase an aggregate of up to 2 million of the Company’s ADSs, at an exercise price of USD 3.25 per ADS. The holders agreed to exercise their March 2020 warrants in full, for gross proceeds of approximately USD 6.5 million (approximately USD 5.4 million net of placement agent fees including non- cash fees and other offering related expenses). In exchange for exercising the warrants the Company issued an aggregate of 2 million ADS, that were recorded in equity in the amount of USD 3,170 thousand. Under the exercise agreement, the Company also issued to the holders, in a private placement, new unregistered warrants to purchase up to an aggregate of 2.2 million ADSs at an exercise price of USD 3.25 per ADS (hereinafter the “new April 2020 warrants”). The new April 2020 warrants were exercisable immediately and had an exercise period of 5.5 years from the date of the issuance. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability in the amount of USD 5,283 thousand. On May 20, 2020 the warrants were listed for trading, and, as a result the cashless feature expired. Therefore, the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value was recorded as financial expenses. The warrants fair value on the listing date was USD 10,982 thousand. The change in the fair value of these derivative instruments is primarily due to the change in the Company’s share price between April 19, 2020 and May 20, 2020 which is reflected in the expected volatility. In addition, the Company issued to the placement agent (or its designees) warrants to purchase up to 140,000 ADSs at a value of USD 315 thousand which is included in the net amount raised above, which have the same terms as the new April 2020 warrants except for an exercise price of USD 4.0625 per ADS. On March 16, 2020, in a public offering on the NASDAQ, the Company raised USD 6 million gross (approximately USD 4.6 million net of placement agent fees including non- cash fees and other offering related expenses). In this public offering, the Company issued an aggregate of 962,000 ADS that were recorded in equity in the amount of USD1,674 thousand gross and 1,038,000 pre-funded warrants which were immediately exercised (an exercise price of USD 0.001 per each ADS) and which were recorded in receipts on account of warrants in the amount of USD 1,806 thousand gross, and warrants to purchase an aggregate of up to 2,000,000 ADSs (hereinafter the “March 2020 warrants”) that were recorded in receipts on account of warrants in the amount of USD 2,520 thousand gross. The March 2020 warrants were exercisable at an exercise price of USD 3.25 per ADS and had a term of exercise period of 5 years from the date of the issuance. In addition, the Company issued to the placement agent (or its designees) warrants to purchase up to 140,000 ADSs at a value of USD 241 thousand which is included in the net amount raised above. The placement agent warrants are exercisable at an exercise price of USD 3.75 per ADS and will terminate on March 12, 2025. 129,861 ADSs were issued in connection with the 2020 transactions to a former placement agent and its cost is included in the net amounts raised above. See note 5 for additional ADS and warrants issued during the period. 2. In January 2019, in a registered direct offering on the NASDAQ, the Company raised USD 6 million gross (approximately USD 5.1 million net of placement agent fees and other offering related expenses). Part of the issuance expenses were warrants issued to the placement agent in the amount of USD 298 thousand were recorded in equity. USD 129 thousand were recorded net of share premium and USD 169 thousand were recorded to finance expense. In this registered direct offering, the Company issued 342,857 ADSs and, in a concurrent private placement, 257,143 non-listed warrants to purchase 257,143 ADSs. Each non-listed warrant is exercisable until July 15, 2024 at an exercise price of USD 20.00 per ADS. The ADSs issued were recorded in equity in an amount of USD 2,200 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature), and were recorded as a liability in the amount of USD 3,406 thousand. Issuance expenses related to the warrants, in the amount of USD 515 thousand were recorded to finance expense. During September 2019, the warrants were listed for trading, and as a result the cashless feature expired. Therefore, the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The change in the warrants fair value was recorded as financial income. The warrants fair value on the listing date was USD 1,273 thousand. 3. In June 2018, in a registered direct offering on the NASDAQ, the Company raised a gross amount of USD 8.1 million (approximately USD 7.4 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 326,000 ADSs and, in a concurrent private placement, 163,000 non-listed warrants to purchase 163,000 ADSs. Each non-listed warrant is exercisable until December 5, 2023 at an exercise price of USD 28. 0 per ADS. The ADS’s issued were recorded in equity in an amount of USD 4,276 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability in the amount of USD 3,467 thousand. Issuance expenses related to the warrants, in the amount of USD 301 thousand were recorded to finance expenses. During September 2019, the warrants were listed for trading, and as a result the cashless feature expired. Therefore, the Company reclassified the warrants to equity according to the warrants fair value on the listing date. The changes in the warrants fair value were recorded as financial income. The warrants fair value on the listing date was USD 661 thousand. E. Other equity transactions 1. During 2021, the Company issued 1,634 thousand ordinary shares on account of vested RSUs granted in 2020 to officers, board members and employees. 2. During 2020, the Company issued 11 thousand ordinary shares on account of vested RSUs granted in 2017 and 2018 and 54 thousand fully vested RSUs were granted to an officer, See also Note 11A. 3. During 2020, 6,675 thousand warrants, issued in March- June 2020, were exercised into 56,366 thousand ordinary shares. Subsequently, an amount of USD 23,780 thousand was recorded to share premium against receipts on accounts of warrants. 4. During 2020 the Company acquired 100% of FameWave Ltd for equity, See Note 5B. 5. During 2019, the Company issued 97 thousand ordinary shares on account of vested RSUs granted in 2017 and 2018. See also Note 11A. 6. During 2019, 29 thousand warrants, issued in July 2017, were exercised into 29 thousand shares for a consideration of USD 43 thousand. Subsequently, an amount of USD 42 thousand was recorded to share premium against receipts on accounts of warrants. Notes to the Consolidated Financial Statements F. Non-controlling interests The following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations: December 31 December 31 TyrNovo Ltd. in USD thousand Non-current assets 11 16 Current assets 976 174 Current liabilities (11,806 ) (5,543 ) Net assets (10,819 ) (5,353 ) Net assets attributable to non-controlling interests (166 ) (82 ) Loss for the year 5,467 4,922 Loss allocated to non-controlling interests 84 75

Share-based Payment Arrangement

Share-based Payment Arrangements	12 Months Ended
	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Share-based Payment Arrangements	Note 11 - Share-based Payment Arrangements A. On November 7, 2021, the board of directors of the Company granted 112 thousand options and 112 thousand RSUs to new director, subject to his election in the annual general meeting. The options have an exercise price of USD 0.470 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 73 thousand. This grant together with June grant to directors was approved by the shareholders on December 29, 2021 and the vesting period begun accordingly. On August 31, 2021, the board of directors of the Company granted 420 thousand options and 420 thousand RSUs to new officer and employee. The options have an exercise price of USD 0.492 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 268 thousand On June 7, 2021, the board of directors of the Company granted 638 thousand options and 488 thousand RSUs to directors, officers and employees. The options have an exercise price of USD 0.470 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 406 thousand. This grant to directors was approved by the shareholders in December 29, 2021 and the vesting period begun accordingly. On October 12, 2020, the board of directors of the Company granted 232 thousand options and 232 thousand RSUs to new officer and employees. The options have an exercise price of USD 0.432 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 171 thousand. On May 18, 2020, the board of directors of the Company granted 1,853 thousand options and 1,853 thousand RSUs to officers and employees. The options have an exercise price of USD 0.421 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 1,845 thousand. In addition, the board of directors of the Company granted a total of 1,463 thousand options and 1,463 thousand RSUs to the Chief Executive Officer, Chairman of the Board of Directors and the other directors. This grant was approved by the shareholders in August 2020. The options have an exercise price of USD 0.421 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 2,342 thousand. On April 2, 2020, the Company granted 178 thousand options to an officer. 151 thousand options have an exercise price of USD 0.347 per one ordinary share, and will vest over 3 years from the grant date. The options are exercisable for 7 years from grant date. The fair value of these options as of the grant date was measured at USD 40 thousand. An additional 27 thousand options were granted that have an exercise price of USD 1.98 per one ordinary share, and will vest over 3 years from the grant date. The options are exercisable for 4 years from grant date. The fair value of these options as of the grant date was measured at USD 3 thousand. In addition, 54,472 RSUs were granted which are fully vested, See Note 5B. On December 18, 2019, the Company granted 335 thousand options to an officer. The options have an exercise price of USD 0.79 per one ordinary share, and will vest over 3 years from the grant date. The options are exercisable for 7 years from grant date. The fair value of these options as of the grant date was measured at USD 221 thousand. On December 23, 2019, the Company granted 400 thousand options to the Chairman of the Board. The options have an exercise price of USD 0.814 per one ordinary share, and will vest during 3 years from the grant date. The options are exercisable for 7 years from grant date. This grant was approved by the shareholders in December 2019. The fair value of these options as of the grant date was measured at USD 207 thousand. During March and April 2019, the board of directors of the Company approved the grant of 3,162 thousand options to directors, officers, employees and consultants. The options have an exercise price of USD 1.28 – 1.64 per one ordinary share, and will vest during 3 years from the date of grant. The options are exercisable for 5-7 years from grant date. The fair value of these options as of the grant date was measured at USD 2,677 thousand. Those options that were granted to directors were approved by the shareholders of the Company in April 2019. In addition, the Company granted 61 thousand options to Tmura, an Israeli charity organization, the options have an exercise price equals USD 6 per ordinary share, and were immediately vested at the date of grant. The fair value of these options as of the grant date was measured at USD 56 thousand. The Company recorded in 2021 an expense for share-based payment arrangements of USD 2,082 thousand (2020 - USD 2,645 thousand, 2019- USD 1,273 thousand), of which USD 1,924 thousand (2020 - USD 2,409 thousand, 2019 - USD 988 thousand) are to officers and directors. B. The number and weighted average exercise prices (in USD) of share options are as follows: Weighted average exercise price Number of options 2021 2020 2019 2021 2020 2019 Outstanding on January 1 1.02 1.71 2.6 6,994,377 4,754,676 1,131,781 Expired and forfeited during the year 1.52 0.23 - (413,074 ) (1,486,125 ) - Granted during the year 0.47 0.43 1.32 1,170,000 3,725,826 3,622,895 Outstanding on December 31 0.97 1.02 1.71 7,751,303 6,994,377 4,754,676 Exercisable on December 31 1.48 1.54 3.21 4,451,430 1,753,632 1,093,029 The exercise price is denominated in NIS and are re-measured using historic exchange rates. Options are exercisable to shares, each ADS represent 10 shares. The options outstanding at December 31, 2021 had an exercise price of USD 0.346- USD 6 (2020 - USD 0.346- USD 6, 2019 -USD 0.81 - USD 6), and weighted average contractual life of 3.9 years (2020 - 5.89 years, 2019 - 5.56 years). C. The number of RSUs are as follows: Number of RSUs 2021 2020 Outstanding at January 1 3,390,000 11,509 Granted during the year 1,020,000 3,601,972 Forfeited during the year 166,250 157,500 Vested during the year 1,633,750 65,981 Outstanding at December 31 2,610,000 3,390,000 Each RSU is convertible to one share, each ADS represent 10 shares. D. Options to service providers were measured at the fair value of the service, when available. The fair value of the Company’s share options granted to employees, directors and consultants, where fair value of service was not measurable, was measured using the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific terms of the options based on the expected duration. E The following assumptions were used : 2021 2020 2019 Share Price - USD 0.380 - 0.517 0.32-0.898 0.746-1.22 Exercise price - USD 0.470-0.492 0.346-0.432 0.792-6 Expected volatility (%) 95.07-96.1 95.68-107 99.22-113.78 Expected duration (years) 2-5 4-7 4.61-7 Dividend yield (%) - - - Risk free rate interest rate (%) 0.87%-1.166 % 0.298%-0.5 % 1.63%-1.95 % F. Expenses recognized in the consolidated financial statements: For the year ended December 31 2021 2020 2019 USD thousands Research and development expenses 557 756 238 General and administrative expenses 1,525 1,889 1,035 Total share-based expense recognized 2,082 2,645 1,273

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2021
Disclosure of transactions between related parties [text block] [Abstract]
Transactions and Balances with Related Parties	Note 12 - Transactions and Balances with Related Parties In addition to their salaries or fees, the Group also provides share option programs to directors and officers and contributes to a post-employment defined contribution plan on behalf of employees, see Note 9 for the balances and Note 11 regarding share based payments. Certain officers are entitled to termination benefits of up to 6 monthly salaries or fees, See Note 18. Officers also participate in the Group’s share option programs. For further information, see Note 11 regarding share-based payments. Expenses of key management personnel: The Company recorded expenses to executive officers: For the year ended December 31 2021 2020 2019 USD thousands Short - term employee benefits 2,402 1,982 1,776 Post-employment benefits 27 19 22 Share based payments 1,446 1,667 719 3,875 3,668 2,517 The Company recorded expenses to directors: For the year ended December 31 2021 2020 2019 USD thousands Short - term benefits 323 306 339 Share based payments 478 742 269 801 1,048 608

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2021
Disclosure of commitments and contingent liabilities [text block] [Abstract]
Commitments and contingent liabilities	Note 13 - Commitments and contingent liabilities A. Commitments 1. TyrNovo, has obligations to the Israel Innovation Authority (hereinafter: “IIA”) with respect to grants it received from the IIA in connection with TyrNovo’s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 and in the IIA’s rules and guidelines and the terms of these grants. In general, a recipient company is obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of, a research and development program funded by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate amount of the total grants received by the IIA, plus annual interest. The recipient company is also obligated to manufacture its drug in Israel unless it receives the approval of the IIA in which case it will be required to pay the higher rate mentioned above. Tyrnovo will not be required to repay the grants if it does not generate revenue. TyrNovo’s technologies were developed, in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its IIA funded products and related services. As of December 31, 2021, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.8 million), and as of such date, TyrNovo had not paid any royalties to the IIA. The Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties. 2. TyrNovo has entered into a license agreement (the “License Agreement”) with Yissum Research Development company of the Hebrew University of Jerusalem Ltd. (hereafter “Yissum”) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer to sell, or sell products, that are derived from Yissum’s licensed technology. In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement. The consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is no minimum payments and thus obligation will be recognized when the related sales will occur. 3. FameWave has entered into a license agreement with Tel Hashomer – Medical Research Infrastructure and Services Ltd. (“THM”) and Ramot at Tel Aviv University Ltd. (“Ramot”) dated April 16, 2012, which was effective as of May 25, 2010, as subsequently amended (the “THM License Agreement”). Pursuant to the THM License Agreement, THM and Ramot granted FameWave a worldwide, royalty-bearing, exclusive license to develop, manufacture, produce, market and sell any biopharmaceutical product and/or diagnostic product using patents and inventions owned by THM and Ramot in connection with uses of the glycoprotein CEACAM1. In consideration for the license grant, FameWave shall pay to THM the following during the term of the license: i) An annual license fee of $10,000 which is credited towards any royalties to be paid during such year. ii) Royalties of three- and one-half (3.5%) of net sales with respect to Biopharmaceutical Products, and royalties of six- and one-half (6.5%) of net sales with respect to Diagnostic Products. iii) Sublicense fees at a rate of twenty percent (20%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (12%) of sublicense consideration with respect to Diagnostic Products. FameWave has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones. In addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three- and one-half percent (3.5%) of all consideration received because of or in connection with an exit event (as defined in the THM License Agreement). Finally, THM also received an assignable warrant to purchase, upon the closing of any IPO of FameWave, ordinary shares of FameWave, at a price equal to a certain percentage of the forecast initial market value of FameWave for each share as was determined, prior to the IPO, for the purpose of the IPO. In accordance with the THM License Agreement, THM is entitled to appoint an observer to FameWave’s board of directors who has all the rights of any other director of FameWave expect for the right to vote. To date, THM has not acted on this right. The consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is no minimum payments and thus obligation will be recognized when the related sales will occur. B. Claims 1. In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed in the Tel Aviv District Court (Economic Division) against the Company and its directors by shareholders who were holding the Company’s Tel Aviv Stock Exchange listed securities before the Company’s initial public offering in the United States (the “U.S. IPO”) that took place in November 2015, claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 5.3 million) due to the U.S. IPO (the “Motion”). In addition to this amount, the petitioners in the motion are seeking remedies in order to redress discrimination against the purported class owing to the dilution caused by the public offering, including the possibility that the purported class should be awarded from the Company amounts reflecting the losses of the purported class from a possible price increase in our shares following the announcement of the Phase III clinical trial results. The Company delivered its response to the court. A preliminary hearing was held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion. Additional preliminary hearings were held during 2017. On October 24, 2017 the court issued a ruling to stay proceedings in this matter until January 15, 2018 due to the ongoing ISA Investigation (See Note 13B(3) below). At the request of the ISA, this stay was subsequently extended several times by the court. Following approval of the Enforcement Arrangement in connection with the ISA Investigation (see Note 12B(3)), the stay was lifted. An evidentiary hearing has been scheduled for April 27, 2022. In consultation with its legal advisors, the Company believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 2. On November 8, 2016, a shareholder of the Company submitted a request to the court in connection with the Motion to be excluded from the purported class, claiming to have independent causes of action and damages of approximately NIS 1 million (USD 322 thousand) The Company rejects the claims asserted in the Motion as well as in the Petition to Exclude and the Separate Lawsuit, and, in consultation with its legal advisors, believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 3. In February 2017 the Company announced that the Israeli Securities Authority (the “ISA”) has begun a formal investigation into, amongst other matters, the Company’s public disclosures around certain aspects of the studies related to its therapeutic candidate, Consensi. In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a “Motion”), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), with each Motion relating to the ISA Investigation (the “2017 Motions”). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other two of the 2017 Motions (“Petition for Dismissal”). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the “Surviving Motion”) was filed against the Company, the Company’s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition an aggregate loss of approximately NIS 29 million (approximately USD 9.3 million). The court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of the Enforcement Arrangement in connection with the ISA Investigation, the stay was lifted. On May 29, 2020 the petitioners in the Surviving Motion filed an amended lawsuit and motion to approve the lawsuit as a class action. On November 15, 2020, the respondents filed their responses to the amended motion to approve the lawsuit as a class action. Following the submission of these responses, and as suggested by the court, the parties attended mediation, but without success. The plaintiffs then filed a motion to submit a new expert opinion as a response to the respondents’ claims. The court approved the motion on January 3, 2022, and set a date for the plaintiffs’ answer to the respondents’ responses and expert opinion to be filed on April 4, 2022. The Company rejects the claims in the Surviving Motion. In consultation with its legal advisors, the Company believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 4. On February 7, 2017, a holder of the Company’s securities listed on the NASDAQ filed in the United States District Court (Southern District of New York) a federal securities class action against the Company, its CEO and former CFO largely relating to the same matters that were the subject of the ISA Investigation. On February 10, 2017, a holder of the Company’s securities listed on the NASDAQ filed in the Superior Court of the State of California a securities class action against the Company, its CEO and former CFO and the underwriters in the Company’s initial public offering in the U.S. on November 20, 2015 largely relating to the same matters that were the subject of the ISA Investigation. The Company finalized a settlement agreement with respect to both class actions lawsuits, which was approved by the court on March 22, 2019. Under the terms of the settlement, the classes in all of the actions received aggregate consideration of $2.0 million (the “US Settlement”). The US Settlement consideration, as well as ancillary expenses, were funded by the Company’s insurance carriers. The US Settlement contained no admission of wrongdoing and reiterates that the Company has always maintained and continues to believe that it did not engage in any wrongdoing or otherwise commit any violation of federal or state securities laws or other laws, including, without limitation, vigorous denials that the Company’s public statements were misleading; that the Company failed to disclose any material information from investors; that the Company acted in any deceitful manner; that any investment losses sustained by the classes were caused by the Company or other defendants’ alleged misconduct, and that they have any liability to the classes in these actions. The US Settlement also reiterates that the Company’s counsel has researched the applicable law and believes that the Company and other defendants can successfully defend against all claims in the actions, and that they continue to believe that the claims asserted in the actions have no merit, and the classes have no evidence to support their claims. 5. On August 13, 2019, the Administrative Enforcement Committee (the “Committee”) of the ISA approved an administrative enforcement agreement, titled Enforcement Arrangement (“Enforcement Arrangement”), entered into by and among the ISA, the Company, Isaac Israel, the Company’s chief executive officer, Dr. Paul Waymack, the Company’s former chairman, and Simcha Rock, the Company’s former CFO pursuant to which the Company and each of Messrs. Israel, Waymack and Rock settled the ISA’s claims that under Israeli Securities Laws the Company made negligent disclosures in a number of its historical reports filed with the ISA in 2014 and 2015, and the ISA decided to discontinue its criminal investigation and to cease all proceedings against the Company and its principals. As part of the Enforcement Arrangement the Company paid a fine of NIS 1,500,000 (approximately USD 482 thousand), in 24 consecutive monthly payments from September 2019. 6. On December 21, 2020, the Bar Ilan University and BIRAD Research & Development Company Ltd. (the “University” and “BIRAD”, respectively) filed a statement of claim to the court against TyrNovo, its officer and others. In the claim, the petitioners allege that the University is the rightful owner of a patent owned by TyrNovo. The invention underlying the patent application is based on experiments which were performed under a services agreement between BIRAD and TyrNovo. The main remedy sought by the petitioners is a declaratory relief under which the University is declared the owner of such patent. At this preliminary stage we are unable, with any degree of certainty, to make any evaluations or any assessments with respect to the probability of success or the scope of potential exposure, if any.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2021
Research and Development Expenses [Abstract]
Research and Development Expenses	Note 14 - Research and Development Expenses For the year ended December 31 2021 2020 2019 USD thousands Salaries, wages and related expenses 1,721 1,209 804 Share-based payments (see also Note 11) 557 756 238 Service providers 9,549 5,273 1,236 11,827 7,238 2,278

Sales, General and Administrati

Sales, General and Administrative Expenses	12 Months Ended
	Dec. 31, 2021
Sales, General and Administrative Expenses [Abstract]
Sales, General and Administrative Expenses	Note 15 - Sales, General and Administrative Expenses A. For the year ended December 31 2021 2020 2019 USD thousands Employees and officer’s compensation 1,762 1,332 1,397 Share-based payments (see also Note 11) 1,047 1,147 657 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B) 12 43 356 Reimbursement of legal fees (66 ) (182 ) (596 ) Other professional fees 1,222 1,215 805 Board member remuneration and insurance 1,033 962 622 Board member share-based payments 478 742 269 ISA settlement (see also Note 13B) - - 387 Maintenance expenses 55 58 80 Travel and car expenses 133 76 182 Depreciation 231 235 178 Other 200 373 56 6,107 6,001 4,393 B. The Consolidated Statements of Operations for the year ended December 31, 2021, 2020 and 2019 include refunds from the insurance company in respect of legal expenses in the amount of USD 66 USD 182 and USD 596 thousand, respectiveley.

Finance Expense (Income), Net

Finance Expense (Income), Net	12 Months Ended
	Dec. 31, 2021
Disclosure of trading income (expense) [text block] [Abstract]
Finance Expense (Income), net	Note 16 - Finance Expense (Income), net A. Expenses (income) on account of warrants These expenses (income) are related mainly to the fair value adjustments of warrants. The 2020 and 2019 warrants included a cashless exercise feature, which expired on July 17, 2020, May 20, 2020, September 12, 2019, respectively, when the Company filed a registration statement with the SEC, registering the shares that will derive from future exercise of these warrants. See also Note 19B. B. Finance expenses For the year ended December 31 2021 2020 2019 USD thousands Finance expenses Fees and interest expense 79 56 81 Loss from exchange rate differences, net 133 5 100 212 61 181

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2021
Disclosure of income tax [text block] [Abstract]
Taxes on Income	Note 17 - Taxes on Income A. Corporate tax rate The tax rate applicable to the Group for 2019 - 2021 is 23%. B. Carry-forward losses The Company and its subsidiaries incurred losses through 2021, which are not expected to be utilized in the foreseeable future. Therefore, the Group did not record current taxes or deferred taxes. In 2021, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 4.2 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of carry forward tax losses and in respect of unrecognized expenses for tax purposes such as changes in fair value of warrants. The carry-forward loss for tax purposes of the Company and its subsidiaries, and the unrecognized research and development expenses, amounts to USD 59 million as of December 31, 2021 (2020 – USD 41 million, 2019 – USD 21 million). C. Tax assessments The Company’s tax assessments are deemed finalized through the end of 2017, pursuant to section 145 of the Israeli Income Tax Ordinance. Tyrnovo’s tax assessment is deemed finalized through the end of 2016 and Famewave’s tax assessment is open (incorporated on July 2, 2017), pursuant to section 145 of the Israeli Income Tax Ordinance. During 2019, the Company’s tax assessments for Purple Biotech Ltd. for the tax years of 2014 - 2017 were finalized. Following the tax assessments, the Company was required to pay an amount of approximately 250 USD thousands which were recorded as an expense in 2019.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2021
Disclosure of employee benefits [text block] [Abstract]
Employee benefits	Note 18 - Employee benefits A. Employee benefits include post-employment benefits and short-term benefits. Balances include: For the Year ended December 31 2021 2020 USD USD Short-term benefits 432 263 Post-employment benefits 292 265 B. Post-employment benefit plans – defined contribution plan The Company has a defined contribution plan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. For the Year ended December 31 2021 2020 2019 USD USD USD Amount recognized as expense in respect of defined contribution plan 291 197 136 C. Certain of the Company’s executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements for the commercialization of the Company’s products. These consolidated financial statements include bonuses expenses in the amount of USD 580 thousand for the year ended December 31, 2021, USD 481 thousand for the year ended December 31, 2020, and USD 462 thousand for the year ended December 31, 2019. D. Certain of the Company’s executives are entitled to benefits upon termination of employment under the terms of their employment and consulting agreements, see Note 12 on related parties. These benefits are measured based on the time of service and their monthly pay and the expected term of their employment. These consolidated financial statements include a liability due to these grants of USD 292 thousand and USD 265 thousand, as of December 31, 2021 and 2020, respectively.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2021
Disclosure of financial instruments [text block] [Abstract]
Financial Instruments	Note 19 - Financial Instruments Framework for risk management The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk management framework. The Group’s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods are reviewed regularly to reflect changes in market conditions and in the Group’s operations. The Group acts to develop an effective control environment in which all employees understand their roles and commitment. The Group Audit Committee oversees how management monitors compliance with the Group’s risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee. A. Risk management 1 Credit risk Credit risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations, and arises mainly from the Company’s receivables. The Group restricts exposure to credit risk by investing only in bank deposits. The Group held cash and cash equivalents and short-term and long-terms deposits of USD 47,360 thousand at December 31, 2021 (2020 – USD 60,876 thousand). These are held with banks, which are rated A2, based on Moody’s Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between 0.43% - 1.05%, and the long-term deposits, mainly in NIS, bear fixed interest of 0.1%. The carrying amount of cash and cash equivalents and short-term deposits approximate their fair value. The Group at December 31, 2021 has an amount of USD 160 thousand in long term deposits guaranteed for the Group’s leases and credit. 2. Market risk Market risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity instruments, will influence the Group’s results or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns. Currency risk The Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in NIS and EURO. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the dollar and takes steps to reduce the currency risk by maintaining its liquid resources in accordance with its future needs. Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2021: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 38 94 1,877 (94 ) (38 ) Other current assets 24 59 1,185 (59 ) (24 ) Accounts payable (13 ) (33 ) (661 ) 33 13 Other payables (39 ) (99 ) (1,970 ) 99 39 Post-employment benefit liabilities (6 ) (15 ) (292 ) 15 6 Total income (loss) 4 6 (6 ) (4 ) B. Financial instruments measured at fair value: 1. In October 2021, the Company received a convertible note in the amount of $1.5 million and 300 thousand warrants as part of Coeptis termination at an exercise price of $5. The warrants are exercisable until September 21, 2024. This convertible debt instrument does not meet the solely payments of principal and i 2. In July 2020 and May 2020, the Company registered the warrants issued in May 2020 and April 2020, respectively, and therefore they were reclassified from financial liabilities to equity in their fair value using Black & Scholes valuation method. 3. Fair value hierarchy of financial instruments measured at fair value: December 31, 2021 Level 1 Level 2 Level 3 Total USD thousands Financial asset Convertible debt instrument (see Note 19B(1)) 187 187 Details regarding fair value measurement at Level 3: Financial instrument Valuation Significant For the year ended December 31, 2021 Convertible debt instrument Black - Scholes expected term 2.75 years expected volatility 125 % annual risk free interest 0.97 % dividend yield 0 % For the year ended December 31, 2020 Warrants Black - Scholes expected term 5.3-5.42 years expected volatility 107.17%-108.9% annual risk free interest 0.40%-0.50% dividend yield 0 %

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of consolidation	A. Basis of consolidation 1. Acquisition of Subsidiaries The Group has acquired two subsidiaries in the past, see Note 5. Upon such acquisition, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts for the acquisition as a purchase of assets. To date, the two acquisitions made by the Company were determined to be an acquisition of assets, see Note 5. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. 4. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. B. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end of the year. The foreign currency gain or loss on amortized items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. C. Financial instruments 1. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. Subsequent measurement and gains and losses Financial assets at fair value through profit or loss These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include: finance lease liabilities, accounts payables and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. 3. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3. 4. Share capital Ordinary shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects. Incremental costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. 5. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufactuing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo and Famewave (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end of the year. The foreign currency gain or loss on amortized items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.
Financial instruments	C. Financial instruments 1. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes trade receivables and debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. A trade receivable without a significant financing component is initially measured at the transaction price. Receivables originating from contract assets are initially measured at the carrying amount of the contract assets on the date classification was changed from contract asset to receivables. Derecognition of financial assets Financial assets are derecognized when the contractual rights of the Group to the cash flows from the asset expire, or the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. When the Group retains substantially all of the risks and rewards of ownership of the financial asset, it continues to recognize the financial asset. Classification of financial assets into categories and the accounting treatment of each category Financial assets are classified at initial recognition to one of the following measurement categories: assets at amortized cost; assets at fair value through other comprehensive income – investments in debt instruments; assets at fair value through other comprehensive income – investments in equity instruments; or assets at fair value through profit or loss. Financial assets are not reclassified in subsequent periods unless, and only if, the Group changes its business model for the management of financial debt assets, in which case the affected financial debt assets are reclassified at the beginning of the period following the change in the business model. Subsequent measurement and gains and losses Financial assets at fair value through profit or loss These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include: finance lease liabilities, accounts payables and other payables. Initial recognition of financial liabilities The Group initially recognizes debt securities issued on the date that they originated. All other financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Subsequent measurement of financial liabilities Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Financial liabilities are designated at fair value through profit or loss if the Group manages such liabilities and their performance is assessed based on their fair value in accordance with the Group’s documented risk management strategy, providing that the designation is intended to prevent an accounting mismatch, or the liability is a combined instrument including an embedded derivative. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. 3. Derivative financial liabilities The Group holds derivative financial instruments that do not serve for hedging purposes. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation, and classified as level 3. 4. Share capital Ordinary shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity, net of any tax effects. Incremental costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. 5. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufactuing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo and Famewave (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization
Intangible assets	D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufactuing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo and Famewave (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment may be needed.
Impairment	E. Impairment Timing of impairment testing The carrying amounts of the Group’s non-financial assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains goodwill, or intangible assets that have indefinite useful lives or are unavailable for use. Measurement of recoverable amount The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. Recognition of impairment loss An impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.
Loss per share	F. Loss per share The Group presents basic and diluted loss per share data for its ordinary share capital. Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of 10 shares per 1 ADS. Diluted loss per share is determined by adjusting the profit or loss attributable to ordinary shareholders of the Company and the weighted average number of ordinary shares outstanding, after adjustment for treasury shares, for the effects of all dilutive potential ordinary shares, which comprise convertible debentures, share options and share options granted to employees.
Employee benefits	G. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. Defined contribution plans A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Short-term benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Share-based payment transactions	I. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest.
Provisions	J. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. A provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation can be estimated reliably.
Revenue	K. Revenue The Group recognizes revenue from upfront and milestone payments at the point in time the milestone criteria are met and collectability is probable Identifying the contract The Group accounts for a contract with a customer only when the following conditions are met: (a) The parties to the contract have approved the contract (in writing, orally or according to other customary business practices) and they are committed to satisfying the obligations attributable to them; (b) The Group can identify the rights of each party in relation to the goods or services that will be transferred; (c) The Group can identify the payment terms for the goods or services that will be transferred; (d) The contract has a commercial substance (i.e. the risk, timing and amount of the entity’s future cash flows are expected to change as a result of the contract); and (e) It is probable that the consideration, to which the Group is entitled to in exchange for the goods or services transferred to the customer, will be collected. For the purpose of section (e) the Group examines, inter alia, the percentage of the advance payments received and the spread of the contractual payments, past experience with the customer and the status and existence of sufficient collateral. If a contract with a customer does not meet all of the above criteria, consideration received from the customer is recognized as a liability until the criteria are met or when one of the following events occurs: the Group has no remaining obligations to transfer goods or services to the customer and any consideration promised by the customer has been received and cannot be returned; or the contract has been terminated and the consideration received from the customer cannot be refunded. Identifying performance obligations On the contract’s inception date, the Group assesses the goods or services promised in the contract with the customer and identifies as a performance obligation any promise to transfer to the customer one of the following: (a) Goods or services (or a bundle of goods or services) that are distinct; or (b) A series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. The Group identifies goods or services promised to the customer as being distinct when the customer can benefit from the goods or services on their own or in conjunction with other readily available resources and the Group’s promise to transfer the goods or services to the customer is separately identifiable from other promises in the contract. In order to examine whether a promise to transfer goods or services is separately identifiable, the Group examines whether it is providing a significant service of integrating the goods or services with other goods or services promised in the contract into one integrated outcome that is the purpose of the contract. Determining the transaction price The transaction price is the amount of the consideration to which the Group expects to be entitled in exchange for the license and commercialization agreement. The Group considers the effects of all the following elements when determining the transaction price: variable consideration, the existence of a significant financing component, non-cash consideration, and consideration payable to the customer. Variable consideration The transaction price includes fixed amounts and amounts that may change as a result of discounts, refunds, credits, price concessions, incentives, performance bonuses, penalties, claims and disputes and contract modifications that the consideration in their respect has not yet been agreed by the parties. The Group includes variable consideration, or part of it, in the transaction price only when it is highly probable that its inclusion will not result in a significant revenue reversal in the future when the uncertainty has been subsequently resolved. At the end of each reporting period and if necessary, the Group revises the amount of the variable consideration included in the transaction price. Right to use and right to access To determine whether the Group’s promise to grant a license provides a customer with either a right to access the Group’s IP or a right-to-use the Group’s IP, the Group considers whether a customer can direct the use of, and obtain substantially all of the remaining benefits from, a license at the point in time at which the license is granted. A license is considered a “right-to-use” license when the customer maintains control of the IP upon its transfer. However, if the grantor of the license maintains involvement with the IP after its transfer, and the customer cannot direct the use of, and obtain substantially all of the remaining benefits from the license, then the license is considered a right-to-access license. The license granted by the Company, which relates to its product is granted to a third party which can obtain direct use of, and substantially all of the remaining benefits from the license at the point in time at which the license is granted. The Group will not continue to be involved in any activities that significantly affect the IP at the specific territory. Therefore the Company recognized the license granted as right-to-use license. Principal or agent When another party is involved in providing goods or services to the customer, the Group examines whether the nature of its promise is a performance obligation to provide the defined goods or services itself, which means the Group is a principal and therefore recognizes revenue in the gross amount of the consideration, or to arrange that another party provide the goods or services which means the Group is an agent and therefore recognizes revenue in the amount of the net commission. The Group is engaged with a third party to manufacture its products for the Group’s customer (“the Manufacturing Agreement”). The Group is a principal when it controls the promised goods or services before their transfer to the customer. Indicators that the Group controls the goods or services before their transfer to the customer include, inter alia, as follows: the Group is the primary obligor for fulfilling the promises in the contract; the Group has inventory risk before the goods or services are transferred to the customer; and the Group has discretion in setting the prices of the goods or services. Accordingly, the Company accounts for the manufacturing agreement as an agent on a net basis.
Financing income and expense	L. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of financial assets at fair value through profit or loss and income from short term deposits. Finance expenses include loss from exchange rate differences and interest fee. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities.
Income tax expense	M. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income to the extent they relate to items recognized directly in equity or in other comprehensive income. Current taxes Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Current taxes also include taxes in respect of prior years and any tax arising from dividends. Deferred taxes Deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets that were not recognized are reevaluated at each reporting date and recognized if it has become probable that future taxable profits will be available against which they can be utilized. The Company has yet to recognize deferred tax assets.
Leases	N. Leases Determining whether an arrangement contains a lease On the inception date of the lease, the Group determines whether the arrangement is a lease or contains a lease, while examining if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. In its assessment of whether an arrangement conveys the right to control the use of an identified asset, the Group assesses whether it has the following two rights throughout the lease term: (a) The right to obtain substantially all the economic benefits from use of the identified asset; and (b) The right to direct the identified asset’s use. For lease contracts that contain non-lease components, such as services or maintenance, that are related to a lease component, the Group elected to account for the contract as a single lease component without separating the components. Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Variable lease payments Variable lease payments that depend on an index or a rate, are initially measured using the index or rate existing at the commencement of the lease and are included in the measurement of the lease liability. When the cash flows of future lease payments change as the result of a change in an index or a rate, the balance of the liability is adjusted against the right-to-use asset. Other variable lease payments that are not included in the measurement of the lease liability are recognized in profit or loss in the period in which the event or condition that triggers payment occurs. Depreciation of right-to-use asset After lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over the useful life or contractual lease period, whichever earlier, as follows: office lease 5 years.
Discontinued operations	O. Discontinued operations A discontinued operation is a component of the Group’s business that represents a separate major line of business that has been disposed of or is held for sale or distribution. Classification as a discontinued operation occurs upon disposal or when the operation meets the criteria to be classified as held for sale, if earlier. When an operation is classified as a discontinued operation, the comparative statement of operation is restated as if the operation had been discontinued from the start of the earliest comparative period.

Basis of Preparation of the C_2

Basis of Preparation of the Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of basis of preparation of financial statements [text block] [Abstract]
Schedule of assumptions of carrying amounts of assets and liabilities	Estimate Principal assumptions Possible effects Reference Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities Recoverability of intangible assets The discounted cash flows method includes assumptions such as future expenses, future revenues, successes rate (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate. Impairment of the in-process research and development in profit or loss See Note 5 regarding subsidiaries
Schedule of changes in exchange rates	Representative exchange rate of USD (NIS/USD 1) Date of consolidated financial statements: December 31, 2021 3.110 December 31, 2020 3.215 December 31, 2019 3.456 % Changes in exchange rates for the year ended: December 31, 2021 (3 ) December 31, 2020 (7 ) December 31, 2019 (7.8 )

Discontinued Operation (Tables)

Discontinued Operation (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of discontinued operations [text block] [Abstract]
Schedule of discontinued operation	2021 2020 2019 USD thousands Results of discontinued operation Revenue - 1,000 1,000 Expenses 642 373 1,485 Loss (profit) for the year 642 (627 ) 485 Loss (profit) for the year attributable to the owners of the Company: From continuing operations 17,826 28,701 5,408 From discontinued operation 642 (627 ) 485 Loss (profit) per share – Discontinued operation Basic & diluted loss (profit) per ADS – USD 0.04 (0.05 ) 0.25 Cash flows from discontinued operation Net cash (used in) provide by operating activities (374 ) 1,705 (1,968 ) (374 ) 1,705 (1,968 )

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about intangible assets [text block] [Abstract]
Schedule of intangible assets	USD thousands IPR&D related to TyrNovo (see 5A below) 6,172 IPR&D related to Famewave (see 5B below) 14,310 Total intangible assets 20,482
Schedule of recognized amounts assets acquired and liabilities assumed	USD thousands Cash 69 Intangible assets (1) 14,310 Other receivables 6 Trade payables (2,283 ) Other payables (2,102 ) Total net identifiable assets 10,000

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of cash and cash equivalents [text block] [Abstract]
Schedule of cash and cash equivalents	As of December 31 2021 2020 USD thousands Balance in USD 9,174 10,758 Balance in other currencies 1,716 489 Total cash and cash equivalents 10,890 11,247

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of carrying amounts of right-to-use assets	Office Lease USD thousands Balance as at January 1, 2021 790 Depreciation on right-to-use assets (171 ) Change during the year - Balance as at December 31, 2021 619 Balance as at January 1, 2020 206 Depreciation on right-to-use assets (233 ) Change during the year 817 Balance as at December 31, 2020 790
Schedule of maturity analysis of the company's lease liabilities	December 31, December 31, 2021 2020 USD thousands USD thousands Less than one year 219 210 One to three years 658 840 Total 877 1,050 Current maturities of lease liability 199 207 Long-term lease liability 550 688
Schedule of amounts recognized in profit or loss	2021 2020 USD thousands USD thousands Interest expenses on lease liability 65 41

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Current Assets [Abstract]
Schedule of other current assets	As of December, 31 2021 2020 USD thousands Government authorities 268 197 Prepaid expenses and other receivables 1,005 780 Total other current assets 1,273 977

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of trade and other payables [text block] [Abstract]
Schedule of other payables	As of December 31 2021 2020 USD thousands Due to related parties - payroll related 527 541 Accrued expenses 1,527 880 Government authorities 66 43 Payroll related 440 229 Other payables 18 - 2,578 1,693

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of share capital, reserves and other equity interest [text block] [Abstract]
Schedule of changes in share capital during the year	As of December 31, 2021 As of December, 31, 2020 Number of shares in thousands Authorized Issued and paid-in Authorized Issued and paid-in Shares, no par value 1,000,000 178,001 1,000,000 172,106 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 -
Schedule of changes in share capital during the year	For the year ended December 31 2021 2020 2019 Number of ADSs in thousands Issued as at January 1 17,211 1,956 1,600 Issuance of ADSs (See D below) 126 8,573 343 Vesting of RSUs 163 7 10 Exercise of warrants 300 6,675 3 Issued as at December 31 17,800 17,211 1,956
Schedule of information relating to subsidiary that has material non-controlling interests	December 31 December 31 TyrNovo Ltd. in USD thousand Non-current assets 11 16 Current assets 976 174 Current liabilities (11,806 ) (5,543 ) Net assets (10,819 ) (5,353 ) Net assets attributable to non-controlling interests (166 ) (82 ) Loss for the year 5,467 4,922 Loss allocated to non-controlling interests 84 75

Share-based Payment Arrangeme_2

Share-based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of share-based payment arrangements [text block] [Abstract]
Summary of number and weighted average exercise prices (in USD) of share options	Weighted average exercise price Number of options 2021 2020 2019 2021 2020 2019 Outstanding on January 1 1.02 1.71 2.6 6,994,377 4,754,676 1,131,781 Expired and forfeited during the year 1.52 0.23 - (413,074 ) (1,486,125 ) - Granted during the year 0.47 0.43 1.32 1,170,000 3,725,826 3,622,895 Outstanding on December 31 0.97 1.02 1.71 7,751,303 6,994,377 4,754,676 Exercisable on December 31 1.48 1.54 3.21 4,451,430 1,753,632 1,093,029
Summary of number of RSUs	Number of RSUs 2021 2020 Outstanding at January 1 3,390,000 11,509 Granted during the year 1,020,000 3,601,972 Forfeited during the year 166,250 157,500 Vested during the year 1,633,750 65,981 Outstanding at December 31 2,610,000 3,390,000
Summary of options to service providers were measured at the fair value of the service	2021 2020 2019 Share Price - USD 0.380 - 0.517 0.32-0.898 0.746-1.22 Exercise price - USD 0.470-0.492 0.346-0.432 0.792-6 Expected volatility (%) 95.07-96.1 95.68-107 99.22-113.78 Expected duration (years) 2-5 4-7 4.61-7 Dividend yield (%) - - - Risk free rate interest rate (%) 0.87%-1.166 % 0.298%-0.5 % 1.63%-1.95 %
Summary of share based expenses recognized	For the year ended December 31 2021 2020 2019 USD thousands Research and development expenses 557 756 238 General and administrative expenses 1,525 1,889 1,035 Total share-based expense recognized 2,082 2,645 1,273

Transactions and Balances wit_2

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of transactions between related parties [text block] [Abstract]
Schedule of recorded expenses to executive officers	For the year ended December 31 2021 2020 2019 USD thousands Short - term employee benefits 2,402 1,982 1,776 Post-employment benefits 27 19 22 Share based payments 1,446 1,667 719 3,875 3,668 2,517 For the year ended December 31 2021 2020 2019 USD thousands Short - term benefits 323 306 339 Share based payments 478 742 269 801 1,048 608

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Research and Development Expenses [Abstract]
Schedule of research and development expenses	For the year ended December 31 2021 2020 2019 USD thousands Salaries, wages and related expenses 1,721 1,209 804 Share-based payments (see also Note 11) 557 756 238 Service providers 9,549 5,273 1,236 11,827 7,238 2,278

Sales, General and Administra_2

Sales, General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Sales, General and Administrative Expenses [Abstract]
Schedule of sales, general and administrative expenses	For the year ended December 31 2021 2020 2019 USD thousands Employees and officer’s compensation 1,762 1,332 1,397 Share-based payments (see also Note 11) 1,047 1,147 657 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B) 12 43 356 Reimbursement of legal fees (66 ) (182 ) (596 ) Other professional fees 1,222 1,215 805 Board member remuneration and insurance 1,033 962 622 Board member share-based payments 478 742 269 ISA settlement (see also Note 13B) - - 387 Maintenance expenses 55 58 80 Travel and car expenses 133 76 182 Depreciation 231 235 178 Other 200 373 56 6,107 6,001 4,393

Finance Expense (Income), Net (

Finance Expense (Income), Net (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of trading income (expense) [text block] [Abstract]
Schedule of Finance expenses	For the year ended December 31 2021 2020 2019 USD thousands Finance expenses Fees and interest expense 79 56 81 Loss from exchange rate differences, net 133 5 100 212 61 181

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of employee benefits [text block] [Abstract]
Schedule of post-employee benefits	For the Year ended December 31 2021 2020 USD USD Short-term benefits 432 263 Post-employment benefits 292 265
Schedule of defined contribution plan in respect of its employees	For the Year ended December 31 2021 2020 2019 USD USD USD Amount recognized as expense in respect of defined contribution plan 291 197 136

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of financial instruments [text block] [Abstract]
Schedule of sensitivity test to possible changes in USD/NIS exchange rate	Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 38 94 1,877 (94 ) (38 ) Other current assets 24 59 1,185 (59 ) (24 ) Accounts payable (13 ) (33 ) (661 ) 33 13 Other payables (39 ) (99 ) (1,970 ) 99 39 Post-employment benefit liabilities (6 ) (15 ) (292 ) 15 6 Total income (loss) 4 6 (6 ) (4 )
Schedule of financial instruments measured at fair value	December 31, 2021 Level 1 Level 2 Level 3 Total USD thousands Financial asset Convertible debt instrument (see Note 19B(1)) 187 187
Schedule of fair value measurement	Financial instrument Valuation Significant For the year ended December 31, 2021 Convertible debt instrument Black - Scholes expected term 2.75 years expected volatility 125 % annual risk free interest 0.97 % dividend yield 0 % For the year ended December 31, 2020 Warrants Black - Scholes expected term 5.3-5.42 years expected volatility 107.17%-108.9% annual risk free interest 0.40%-0.50% dividend yield 0 %

General (Details)

General (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2021
Disclosure General [Abstract]
Description of warrants to purchase ADS		The Company’s securities (American Depository Shares (“ADS”)) were listed for trading on the NASDAQ in November 2015 (including a Serries A warrant that expired in November 2020). Each ADS represents 10 ordinary shares with no par value following a reverse split in effect from August 23, 2020 (see Note 10A). Each 10 warrants enable the purchase of 1 ADS.The Company’s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel.
Contract to acquire, percentage	100.00%
Accumulated deficit		$ 95.9
Private and public financing total value		$ 94.4

Basis of Preparation of the C_3

Basis of Preparation of the Consolidated Financial Statements (Details)	12 Months Ended
	Dec. 31, 2021
Disclosure of basis of preparation of financial statements [text block] [Abstract]
Functional and presentation currency, description	These consolidated financial statements are presented in US dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates.

Basis of Preparation of the C_4

Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities	12 Months Ended
	Dec. 31, 2021
Principal assumptions [Member]
Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities [Line Items]
Assessment of probability of contingent liabilities	Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees
Recoverability of intangible assets	The discounted cash flows method includes assumptions such as future expenses, future revenues, successes rate (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate.
Possible effects [Member]
Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities [Line Items]
Assessment of probability of contingent liabilities	Reversal or creation of a provision for a claim
Recoverability of intangible assets	Impairment of the in-process research and development in profit or loss
Reference [Member]
Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of assumptions of carrying amounts of assets and liabilities [Line Items]
Assessment of probability of contingent liabilities	For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities
Recoverability of intangible assets	See Note 5 regarding subsidiaries

Basis of Preparation of the C_5

Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of changes in exchange rates	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of changes in exchange rates [Abstract]
Representative exchange rate (NIS/USD 1)	3.11	3.215	3.456
Changes in exchange rates for the year ended:
Changes in exchange rates for the Year ended	(3.00%)	(7.00%)	(7.80%)

Significant Accounting Polici_2

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2021
Disclosure of significant accounting policies [text block] [Abstract]
Description of Loss Per Share	The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements:
Lease term	5 years

Discontinued Operation (Details

Discontinued Operation (Details)	12 Months Ended
	Dec. 31, 2021
Disclosure of discontinued operations [text block] [Abstract]
Number of operating segments	1

Discontinued Operation (Detai_2

Discontinued Operation (Details) - Schedule of discontinued operation - Discontinued Operation [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Results of discontinued operation
Revenue		$ 1,000	$ 1,000
Expenses	$ 642	373	1,485
Loss (profit) for the year	642	(627)	485
Loss (profit) for the year attributable to the owners of the Company:
From continuing operations	17,826	28,701	5,408
From discontinued operation	$ 642	$ (627)	$ 485
Loss (profit) per share – Discontinued operation
Basic & diluted loss (profit) per ADS – USD (in Dollars per share)	$ 0.04	$ (0.05)	$ 0.25
Cash flows from discontinued operation
Net cash (used in) provide by operating activities	$ (374)	$ 1,705	$ (1,968)
Total	$ (374)	$ 1,705	$ (1,968)

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Millions	Mar. 14, 2019	Mar. 15, 2018	Dec. 31, 2019	Jun. 30, 2018	Jun. 15, 2018	Oct. 31, 2017	Dec. 31, 2021
Intangible Assets (Details) [Line Items]
Acquisition of tyrnovo, description							the Company issued to GHP 564,625 of its Ordinary Shares (the “Consideration Shares”) and paid GHP aggregate cash proceeds of approximately USD 2 million (the “Cash Consideration”) in exchange for 9,570 Ordinary Shares in TyrNovo, which represented approximately 65% of TyrNovo’s shares. In addition, the Company was assigned a loan in the amount of USD 101 thousand which had been made by GHP to TyrNovo (the “TyrNovo Acquisition”). USD 167 thousand of the Cash Consideration was held back by the Company pending the fulfillment of certain conditions as agreed to between the Company and GHP. During 2019 the Company and GHP signed an agreement, according to which the Company paid GHP USD 91 thousand and the remaining amount of USD 76 thousand was retained by the Company to cover any future claims it might have with regards of any matter the above amount was withheld for and is waived by GHP.
Additional acquisition percentage						27.00%
Additional of ordinary shares (in Shares)						4,024
Additional of approximately percentage						27.00%
Issued of ordinary shares		91.90%			97.40%
Outstanding of ordinary shares		91.90%			97.40%
Share capital				4.10%
Issued of shares (in Shares)			13,750
Acquisition of Famewave description	the Company signed an agreement to acquire 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24, (“FameWave”) from its shareholders in exchange for USD 10 million worth of its newly issued ADSs with a long-term lock-up period, priced at USD 12.3 per ADS, plus 50% warrant coverage based on an exercise price of USD 19.8 per ADS with a 4-year term. In addition, the Company provided a loan to FameWave of up to approximately USD 2 million to finance its operation until the closing of the acquisition. The acquisition closed on January 7, 2020.						In consideration of the transfer of the FameWave shares to the Company and completion of the other condition set forth in the acquisition agreement, the aggregate purchase price paid by the Company for 100% of shareholders, and other stake holders (a) 807,561 of the Company’s ADSs, (b) warrants to purchase 403,781 additional ADSs with a term of exercise of 4 years beginning on the date of issuance, and subject to other terms and conditions as set forth herein and in the ‘warrant agreements of the Company (c) 54,472 RSUs and 27,236 options to purchase 27,236 shares of the Company.
Warrants invested (in Dollars)							$ 3.5
Exchange for additional (in Shares)							284,553
Intangible assets recoverable amount percentage							15.60%
Minimum [Member]
Intangible Assets (Details) [Line Items]
Direct ownership of equity			97.60%
Maximum [Member]
Intangible Assets (Details) [Line Items]
Direct ownership of equity			98.47%

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets $ in Thousands	Dec. 31, 2021USD ($)
Intangible Assets (Details) - Schedule of intangible assets [Line Items]
Total intangible assets	$ 20,482
IPR&D related to TyrNovo (see 5A below) [Member]
Intangible Assets (Details) - Schedule of intangible assets [Line Items]
Total intangible assets	6,172
IPR&D related to Famewave (see 5B below) [Member]
Intangible Assets (Details) - Schedule of intangible assets [Line Items]
Total intangible assets	$ 14,310

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of recognized amounts assets acquired and liabilities assumed $ in Thousands	Dec. 31, 2021USD ($)
Schedule of recognized amounts assets acquired and liabilities assumed [Abstract]
Cash	$ 69
Intangible assets	14,310	[1]
Other receivables	6
Trade payables	(2,283)
Other payables	(2,102)
Total net identifiable assets	$ 10,000
[1]	In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise.

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents [Line Items]
Total cash and cash equivalents	$ 10,890	$ 11,247
Balance in USD [Member]
Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents [Line Items]
Total cash and cash equivalents	9,174	10,758
Balance in other currencies [Member]
Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents [Line Items]
Total cash and cash equivalents	$ 1,716	$ 489

Leases (Details)

Leases (Details) $ in Thousands	1 Months Ended
	Sep. 15, 2020USD ($)
Leases (Details) [Line Items]
Agreement lease term	5 years
Percentage of current terms	5.00%
Material Lease Agreements [Member]
Leases (Details) [Line Items]
Agreement lease term	5 years
Lease receivables [member]
Leases (Details) [Line Items]
Lease liability and right-of-use asset (in Dollars)	$ 817
Material lease agreement	5 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of carrying amounts of right-to-use assets - Office Lease [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases (Details) - Schedule of carrying amounts of right-to-use assets [Line Items]
Balance at beginning	$ 790	$ 206
Depreciation on right-to-use assets	(171)	(233)
Change during the year		817
Balance at ending	$ 619	$ 790

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of maturity analysis of the company's lease liabilities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases (Details) - Schedule of maturity analysis of the company's lease liabilities [Line Items]
Total	$ 877	$ 1,050
Current maturities of lease liability	199	207
Long-term lease liability	550	688
Less than one year [Member]
Leases (Details) - Schedule of maturity analysis of the company's lease liabilities [Line Items]
Total	219	210
One to five years [Member]
Leases (Details) - Schedule of maturity analysis of the company's lease liabilities [Line Items]
Total	$ 658	$ 840

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of amounts recognized in profit or loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of amounts recognized in profit or loss [Abstract]
Interest expenses on lease liability	$ 65	$ 41

Other Current Assets (Details)

Other Current Assets (Details) - Schedule of other current assets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other current assets [Abstract]
Government authorities	$ 268	$ 197
Prepaid expenses and other receivables	1,005	780
Total other current assets	$ 1,273	$ 977

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of other payables [Abstract]
Due to related parties - payroll related	$ 527	$ 541
Accrued expenses	1,527	880
Government authorities	66	43
Payroll related	440	229
Other payables	18
Other Payables, Total	$ 2,578	$ 1,693

Equity (Details)

Equity (Details) - USD ($)	Jun. 09, 2021	May 08, 2020	Jun. 25, 2020	Apr. 19, 2020	Mar. 31, 2020	Mar. 16, 2020	Sep. 30, 2019	Jan. 31, 2019	Jun. 30, 2018	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity (Details) [Line Items]
Company issued securities, description										A. The Company’s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class.
Aggregate offering price	$ 50,000,000
Sales agreement (in Shares)	126,160
Average price (in Dollars per share)	$ 4.46
Gross amount	$ 560,000
Placement agent fees and other offering related expenses	$ 540,000
Warrants fair value		$ 16,403,000								$ 1,273
Warrants term		5 years
Warrants to purchase value		$ 559,000
Derivative instrument		$ 9,157,000
Description of public offering						In this public offering, the Company issued an aggregate of 962,000 ADS that were recorded in equity in the amount of USD1,674   thousand gross and 1,038,000 pre-funded warrants which were immediately exercised (an exercise price of USD 0.001 per each ADS) and which were recorded in receipts on account of warrants in the amount of USD 1,806 thousand gross, and warrants to purchase an aggregate of up to 2,000,000 ADSs (hereinafter the “March 2020 warrants”) that were recorded in receipts on account of warrants in the amount of USD 2,520 thousand gross.
Share premium										$ 123,951,000	$ 118,909,000
Description of warrants rights										During 2021, the Company issued 1,634 thousand ordinary shares on account of vested RSUs granted in 2020 to officers, board members and employees.	During 2020, the Company issued 11 thousand ordinary shares on account of vested RSUs granted in 2017 and 2018 and 54 thousand fully vested RSUs were granted to an officer, See also Note 11A.    3.During 2020, 6,675 thousand warrants, issued in March- June 2020, were exercised into 56,366 thousand ordinary shares. Subsequently, an amount of USD 23,780 thousand was recorded to share premium against receipts on accounts of warrants.    4.During 2020 the Company acquired 100% of FameWave Ltd for equity, See Note 5B.	During 2019, the Company issued 97 thousand ordinary shares on account of vested RSUs granted in 2017 and 2018. See also Note 11A.    6.During 2019, 29 thousand warrants, issued in July 2017, were exercised into 29 thousand shares for a consideration of USD 43 thousand. Subsequently, an amount of USD 42 thousand was recorded to share premium against receipts on accounts of warrants.
Non-controlling interests										1.53%
Ads [Member]
Equity (Details) [Line Items]
Warrants to purchase shares (in Shares)		175,000	194,443	140,000	140,000
Warrants term			5 years
Exercise price (in Dollars per share)		$ 5	$ 11.25	$ 4.0625	$ 3.75
Warrants to purchase value			$ 1,199,000	$ 315,000	$ 241,000
Private Placement [Member] | Ads [Member]
Equity (Details) [Line Items]
Placement agent fees and other offering related expenses			30,700,000
Company funds raised			$ 35,000,000
Warrants to purchase shares (in Shares)				2,200,000
Exercise price (in Dollars per share)				$ 3.25
Public offering [Member] | Ads [Member]
Equity (Details) [Line Items]
Placement agent fees and other offering related expenses									$ 7,400,000
Company funds raised									$ 8,100,000
Number of non-tradable warrants (in Shares)				2,000,000
Public offering [Member] | Ads [Member]
Equity (Details) [Line Items]
Company issued securities, description								The ADSs issued were recorded in equity in an amount of USD 2,200 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature), and were recorded as a liability in the amount of USD 3,406 thousand. Issuance expenses related to the warrants, in the amount of USD 515 thousand were recorded to finance expense.
Placement agent fees and other offering related expenses		$ 8,400,000		$ 5,400,000		$ 4,600,000		$ 5,100,000
Company funds raised		$ 10,000,000		6,500,000		$ 6,000,000		6,000,000
Number of non-tradable warrants (in Shares)		2,500,000	3,888,889
Public offering issued value (in Dollars per share)		$ 4	$ 9
Issue of equity		$ 709,000	$ 19,201,000	$ 3,170,000				298,000
Warrants to purchase shares (in Shares)		2,500,000	1,944,444	2,000,000
Warrants fair value			$ 11,472,000	$ 10,982,000
Warrants term		5 years 6 months	5 years	5 years 6 months	5 years
Exercise price (in Dollars per share)		$ 4	$ 9	$ 3.25	$ 3.25
Warrant exercise price										$ 300,000
Warrants to purchase value				$ 5,283,000
Public offering issued by securities (in Shares)					129,861
Share premium								129,000
Finance expenses								$ 169,000
Description of warrants rights								In this registered direct offering, the Company issued 342,857 ADSs and, in a concurrent private placement, 257,143 non-listed warrants to purchase 257,143 ADSs. Each non-listed warrant is exercisable until July 15, 2024 at an exercise price of USD 20.00 per ADS	In this registered direct offering, the Company issued 326,000 ADSs and, in a concurrent private placement, 163,000 non-listed warrants to purchase 163,000 ADSs. Each non-listed warrant is exercisable until December 5, 2023 at an exercise price of USD 28. 0 per ADS. The ADS’s issued were recorded in equity in an amount of USD 4,276 thousand, net of issuance expenses. The warrants were considered a derivative instrument (due to a cashless exercise feature) and were recorded as a liability in the amount of USD 3,467 thousand. Issuance expenses related to the warrants, in the amount of USD 301 thousand were recorded to finance expenses.
Warrant [Member]
Equity (Details) [Line Items]
Warrants fair value							$ 661,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of changes in share capital during the year - shares shares in Thousands	Dec. 31, 2021	Dec. 31, 2020
Ordinary Share [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	1,000,000	1,000,000
Number of shares, Issued and paid-in	178,001	172,106
Class A Preferred Shares [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class B Preferred Shares [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class C Preferred Shares [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class D Preferred Shares [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class E Preferred Shares [Member]
Equity (Details) - Schedule of changes in share capital during the year [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of changes in share capital during the year - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of changes in share capital during the year [Abstract]
Issued as at January 1	17,211	1,956	1,600
Issuance of shares (See Note 5)	126	8,573	343
Vesting of RSUs	163	7	10
Exercise of warrants	300	6,675	3
Issued as at December 31	17,800	17,211	1,956

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of information relating to subsidiary that has material non-controlling interests - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of information relating to subsidiary that has material non-controlling interests [Abstract]
Non-current assets	$ 11	$ 16
Current assets	976	174
Current liabilities	(11,806)	(5,543)
Net assets	(10,819)	(5,353)
Net assets attributable to non-controlling interests	(166)	(82)
Loss for the year	5,467	4,922
Loss allocated to non-controlling interests	$ 84	$ 75

Share-based Payment Arrangeme_3

Share-based Payment Arrangements (Details) - USD ($) $ / shares in Units, $ in Thousands

Nov. 07, 2021

Jun. 07, 2021

Oct. 12, 2020

Apr. 02, 2020

Aug. 31, 2021

Aug. 31, 2020

May 18, 2020

Dec. 23, 2019

Dec. 18, 2019

Apr. 30, 2019

Mar. 31, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 151

Options exercise price (in Dollars per share)

$ 0.347

$ 0.346

$ 0.346

$ 0.81

Vesting period

3 years

Exercisable period

7 years

7 years

Fair value of options and grants measured

$ 40

Additional stock option granted

$ 27

Additional stock option exercise price (in Dollars per share)

$ 1.98

Additional vesting period

3 years

Additional exercisable period

4 years

Additional fair value of options and grants

$ 3

Share-based payment arrangements

$ 2,082

$ 2,645

$ 2,019

American depostiory shares (in Shares)

10

Option oustanding

$ 6

$ 6

$ 6

Weighted average contractual life

3 years 10 months 24 days

5 years 10 months 20 days

5 years 6 months 21 days

Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangements (Details) [Line Items]

Additional fair value of options and grants

54,472

American depostiory shares (in Shares)

10,000

Options [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 61

Options exercise price (in Dollars per share)

$ 6

Fair value of options and grants measured

$ 56

Board of Directors [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 112

$ 638

$ 232

$ 420

$ 1,853

$ 3,162

$ 3,162

$ 1,463

Options exercise price (in Dollars per share)

$ 0.47

$ 0.47

$ 0.432

$ 0.492

$ 0.421

$ 0.421

Vesting period

3 years

Exercisable period

5 years

5 years

5 years

5 years

5 years

5 years

Fair value of options and grants measured

$ 2,677

$ 2,677

Board of Directors [Member] | Bottom of range [Member]

Share-based Payment Arrangements (Details) [Line Items]

Options exercise price (in Dollars per share)

$ 1.28

$ 1.28

Exercisable period

5 years

5 years

Board of Directors [Member] | Top of range [Member]

Share-based Payment Arrangements (Details) [Line Items]

Options exercise price (in Dollars per share)

$ 1.64

$ 1.64

Exercisable period

7 years

Board of Directors [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangements (Details) [Line Items]

Vesting period

3 years

3 years

3 years

3 years

3 years

3 years

Fair value of options and grants measured

$ 73

$ 406

$ 171

$ 268

$ 2,342

$ 1,845

New Director [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 112

Officer and Employee [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 488

$ 232

$ 420

$ 1,853

Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 1,463

Officer [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 178

$ 335

Options exercise price (in Dollars per share)

$ 0.79

Vesting period

3 years

Exercisable period

7 years

Fair value of options and grants measured

$ 221

Chairman Of Board [Member]

Share-based Payment Arrangements (Details) [Line Items]

Stock option granted

$ 400

Options exercise price (in Dollars per share)

$ 0.814

Vesting period

3 years

Fair value of options and grants measured

$ 207

Officers And Directors [Member]

Share-based Payment Arrangements (Details) [Line Items]

Share-based payment arrangements

$ 1,273

$ 1,924

$ 2,409

Share-based Payment Arrangeme_4

Share-based Payment Arrangements (Details) - Summary of number and weighted average exercise prices (in USD) of share options - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary of number and weighted average exercise prices (in USD) of share options [Abstract]
Outstanding on January 1	$ 1.02	$ 1.71	$ 2.6
Outstanding on January 1	6,994,377	4,754,676	1,131,781
Expired and forfeited during the year	$ 1.52	$ 0.23
Expired and forfeited during the year	(413,074)	(1,486,125)
Granted during the year	$ 0.47	$ 0.43	$ 1.32
Granted during the year	1,170,000	3,725,826	3,622,895
Outstanding on December 31	$ 0.97	$ 1.02	$ 1.71
Outstanding on December 31	7,751,303	6,994,377	4,754,676
Exercisable on December 31	$ 1.48	$ 1.54	$ 3.21
Exercisable on December 31	4,451,430	1,753,632	1,093,029

Share-based Payment Arrangeme_5

Share-based Payment Arrangements (Details) - Summary of number of RSUs - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary of number of RSUs [Abstract]
Outstanding at January 1	3,390,000	11,509
Granted during the year	1,020,000	3,601,972
Forfeited during the year	166,250	157,500
Vested during the year	1,633,750	65,981
Outstanding at December 31	2,610,000	3,390,000

Share-based Payment Arrangeme_6

Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service [Line Items]
Dividend yield (%)
Bottom of range [Member]
Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service [Line Items]
Share Price - USD (in Dollars per share)	$ 0.38	$ 0.32	$ 0.746
Option price - USD (in Dollars per share)	$ 0.47	$ 0.346	$ 0.792
Expected volatility (%)	95.07%	95.68%	99.22%
Expected duration (years)	2 years	4 years	4 years 7 months 9 days
Risk free rate interest rate (%)	0.87%	0.298%	1.63%
Top of range [Member]
Share-based Payment Arrangements (Details) - Summary of options to service providers were measured at the fair value of the service [Line Items]
Share Price - USD (in Dollars per share)	$ 0.517	$ 0.898	$ 1.22
Option price - USD (in Dollars per share)	$ 0.492	$ 0.432	$ 6
Expected volatility (%)	96.10%	107.00%	113.78%
Expected duration (years)	5 years	7 years	7 years
Risk free rate interest rate (%)	1.166%	0.50%	1.95%

Share-based Payment Arrangeme_7

Share-based Payment Arrangements (Details) - Summary of share based expenses recognized - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary of share based expenses recognized [Abstract]
Research and development expenses	$ 557	$ 756	$ 238
General and administrative expenses	1,525	1,889	1,035
Total share-based expense recognized	$ 2,082	$ 2,645	$ 1,273

Transactions and Balances wit_3

Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers - Payments To Key Management [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Chief Executive Officer [Member]
Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers [Line Items]
Short - term employee benefits	$ 2,402	$ 1,982	$ 1,776
Post-employment benefits	27	19	22
Share based payments	1,446	1,667	719
Total	3,875	3,668	2,517
Director [Member]
Transactions and Balances with Related Parties (Details) - Schedule of recorded expenses to executive officers [Line Items]
Short - term employee benefits	323	306	339
Share based payments	478	742	269
Total	$ 801	$ 1,048	$ 608

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details) - USD ($) $ in Millions	Feb. 10, 2017	Nov. 08, 2016	Aug. 19, 2019	Feb. 28, 2017	Dec. 31, 2021	Dec. 31, 2015
Commitments and Contingent Liabilities (Details) [Line Items]
Description of maximum royalty amount					As of December 31, 2021, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.8 million), and as of such date, TyrNovo had not paid any royalties to the IIA.
Loss contingency actions taken by court arbitrator or mediator, description		the Motion to be excluded from the purported class, claiming to have independent causes of action and damages of approximately NIS 1 million (USD 322 thousand) (the “Petition to Exclude”). The Company responded to the court and, amongst other arguments, the Company noted that pursuant to the Class Action Lawsuits Law 5766-2006 and the Regulations enacted thereunder, at the current stage of the court proceedings with respect to the 2015 Motion such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. In May 2018, the shareholder filed an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 354 thousand) and for the purposes of the court fees, the amount claimed was reduced to 750,000 NIS (USD 241 thousand) (the “Separate Lawsuit”).
Gains on litigation settlements				$ 9.3
Description of enforcement arrangement			As part of the Enforcement Arrangement the Company paid a fine of NIS 1,500,000 (approximately USD 482 thousand), in 24 consecutive monthly payments from September 2019.
Nis [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Description of motion total amount						In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed in the Tel Aviv District Court (Economic Division) against the Company and its directors by shareholders who were holding the Company’s Tel Aviv Stock Exchange listed securities before the Company’s initial public offering in the United States (the “U.S. IPO”) that took place in November 2015, claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 5.3 million) due to the U.S. IPO (the “Motion”).
Motion total amount						$ 5.3
Aggregate consideration received	$ 2
Bottom of Range [member]
Commitments and Contingent Liabilities (Details) [Line Items]
Annual interest rate of revenues					3.00%
Top of Range [member]
Commitments and Contingent Liabilities (Details) [Line Items]
Annual interest rate of revenues					6.00%
Tyrnovos Technology [Member] | Israel Innovation Authority [Member] | Nis [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Maximum royalty payable excluding interest amount					$ 1.8
Yissum [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Description of license agreement					In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license:    (i) Royalties at a rate of three percent (3%) of net sales.     (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration.  In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.
THM [Member]
Commitments and Contingent Liabilities (Details) [Line Items]
Description of license agreement					In consideration for the license grant, FameWave shall pay to THM the following during the term of the license: i) An annual license fee of $10,000 which is credited towards any royalties to be paid during such year. ii) Royalties of three- and one-half (3.5%) of net sales with respect to Biopharmaceutical Products, and royalties of six- and one-half (6.5%) of net sales with respect to Diagnostic Products. iii) Sublicense fees at a rate of twenty percent (20%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (12%) of sublicense consideration with respect to Diagnostic Products. FameWave has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones. In addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three- and one-half percent (3.5%) of all consideration received because of or in connection with an exit event (as defined in the THM License Agreement).

Research and Development Expe_3

Research and Development Expenses (Details) - Schedule of research and development expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of research and development expenses [Abstract]
Salaries, wages and related expenses	$ 1,721	$ 1,209	$ 804
Share-based payments (see also Note 11)	557	756	238
Service providers	9,549	5,273	1,236
Research and development expense, total	$ 11,827	$ 7,238	$ 2,278

Sales, General and Administra_3

Sales, General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Sales, General and Administrative Expenses [Abstract]
Legal expenses	$ 66	$ 182	$ 596

Sales, General and Administra_4

Sales, General and Administrative Expenses (Details) - Schedule of sales, general and administrative expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of sales, general and administrative expenses [Abstract]
Employees and officer’s compensation	$ 1,762	$ 1,332	$ 1,397
Share-based payments (see also Note 11)	1,047	1,147	657
Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B)	12	43	356
Reimbursement of legal fees	(66)	(182)	(596)
Other professional fees	1,222	1,215	805
Board member remuneration and insurance	1,033	962	622
Board member share-based payments	478	742	269
ISA settlement (see also Note 13B)			387
Maintenance expenses	55	58	80
Travel and car expenses	133	76	182
Depreciation	231	235	178
Other	200	373	56
Sales, General and Administrative Expenses total	$ 6,107	$ 6,001	$ 4,393

Finance Expense (Income), Net_2

Finance Expense (Income), Net (Details) - Schedule of Finance expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance expenses
Fees and interest expense	$ 79	$ 56	$ 81
Loss from exchange rate differences, net	133	5	100
Finance expenses, total	$ 212	$ 61	$ 181

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Disclosure of income tax [text block] [Abstract]
Tax rate	23.00%	23.00%
Carry forward losses description	In 2021, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 4.2 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of carry forward tax losses and in respect of unrecognized expenses for tax purposes such as changes in fair value of warrants.
Unrecognized research and development expenses	$ 59,000	$ 21,000	$ 41,000
Expense amount		$ 250

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of employee benefits [text block] [Abstract]
Bonuses expenses	$ 580	$ 481	$ 462
Employee benefits liability due grants	$ 292	$ 265

Employee Benefits (Details) - S

Employee Benefits (Details) - Schedule of post-employee benefits - Separate management entities [member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Benefits (Details) - Schedule of post-employee benefits [Line Items]
Short-term benefits	$ 432	$ 263
Post-employment benefits	$ 292	$ 265

Employee Benefits (Details) -_2

Employee Benefits (Details) - Schedule of defined contribution plan in respect of its employees - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of defined contribution plan in respect of its employees [Abstract]
Amount recognized as expense in respect of defined contribution plan	$ 291	$ 197	$ 136

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended
	Oct. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Financial Instruments (Details) [Line Items]
Cash and cash equivalents and short-term and long-terms deposits		$ 47,360	$ 60,876
Bear fixed interest, percentage		0.10%
Long term deposits		$ 160
Convertible note amount	$ 1,500
Convertible warrants (in Shares)	300
Termination exercise price (in Dollars per share)	$ 5
Fair value financial instrument		$ 187
Top of Range [member]
Financial Instruments (Details) [Line Items]
Bear fixed interest, percentage		0.43%
Bottom of Range [member]
Financial Instruments (Details) [Line Items]
Bear fixed interest, percentage		1.05%

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	$ 4
Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	6
Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(6)
Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(4)
Cash and cash equivalents and deposits [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) value	1,877
Cash and cash equivalents and deposits [Member] | Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	38
Cash and cash equivalents and deposits [Member] | Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	94
Cash and cash equivalents and deposits [Member] | Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(94)
Cash and cash equivalents and deposits [Member] | Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(38)
Other current assets [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) value	1,185
Other current assets [Member] | Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	24
Other current assets [Member] | Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	59
Other current assets [Member] | Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(59)
Other current assets [Member] | Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(24)
Accounts payable [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) value	(661)
Accounts payable [Member] | Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(13)
Accounts payable [Member] | Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(33)
Accounts payable [Member] | Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	33
Accounts payable [Member] | Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	13
Other payables [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) value	(1,970)
Other payables [Member] | Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(39)
Other payables [Member] | Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(99)
Other payables [Member] | Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	99
Other payables [Member] | Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	39
Post-employment benefit liabilities [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) value	(292)
Post-employment benefit liabilities [Member] | Down Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(6)
Post-employment benefit liabilities [Member] | Down Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	(15)
Post-employment benefit liabilities [Member] | Up Range [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	15
Post-employment benefit liabilities [Member] | Up Range One [Member]
Financial Instruments (Details) - Schedule of sensitivity test to possible changes in USD/NIS exchange rate [Line Items]
Income (loss) from change in exchange rate	$ 6

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of financial instruments measured at fair value $ in Thousands	Dec. 31, 2021USD ($)
Level 1 [Member]
Financial asset
Convertible debt instrument (see Note 19B(1))	$ 187
Level 2 [Member]
Financial asset
Convertible debt instrument (see Note 19B(1))	$ 187

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of fair value measurement	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Financial Instruments (Details) - Schedule of fair value measurement [Line Items]
expected term	2 years 9 months
expected volatility	125.00%
annual risk free interest	0.97%
dividend yield	0.00%	0.00%
Top of Range [member]
Financial Instruments (Details) - Schedule of fair value measurement [Line Items]
expected term		5 years 3 months 18 days
expected volatility		107.17%
annual risk free interest		0.40%
Bottom of Range [member]
Financial Instruments (Details) - Schedule of fair value measurement [Line Items]
expected term		5 years 5 months 1 day
expected volatility		108.90%
annual risk free interest		0.50%